

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Type 2 diabetes is associated with in-hospital complications in women undergoing breast cancer surgical procedures

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-017676
Article Type:	Research
Date Submitted by the Author:	08-May-2017
Complete List of Authors:	Lopez-de-Andres, Ana ; Universidad Rey Juan Carlos, Preventive Medicine and Public Health Teaching and Research Unit. Jimenez-Trujillo, Isabel ; Universidad Rey Juan Carlos, Preventive Medicine and Public Health Teaching and Research Unit Hernandez-Barrera, Valentin; Universidad Rey Juan Carlos, Preventive Medicine and Public Health Teaching and Research Unit de Miguel-Diez, Javier; Hospital General Universitario Gregorio Marañón, Mendez-Bailon, Manuel; Hospital Clinico Universitario San Carlos, Internal Medicine Department de Miguel-Yanes, Jose; Hospital General Universitario Gregorio Maranon, Internal Medicine Department Perez-Farinos, Napoleon; Ministry of Health, Social Services and Equality, Health Security Agency SALINERO-FORT, MIGUEL; Servicio Madrileño de Salud, Gerencia de Atención Primaria del Barrio, Jose; Universidad Rey Juan Carlos Romero-Maroto, Martin; Universidad Rey Juan Carlos Jimenez-Garcia, Rodrigo; Univ Rey Juan Carlos,
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Diabetes and endocrinology
Keywords:	Type 2 diabetes, Breast cancer, mastectomy, breast-conserving surgery, complications, hospitalizations

SCHOLARONE™
Manuscripts

1
2
3 1 **Type 2 diabetes is associated with in-hospital complications in women undergoing**
4
5 2 **breast cancer surgical procedures**
6

7 Ana López-de-Andrés¹, Isabel Jiménez-Trujillo¹, Valentín Hernández-Barrera¹, Javier
8 de Miguel-Díez², Manuel Méndez-Bailón³, José M de Miguel-Yanes⁴, Napoleón Pérez-
9 Farinós⁵, Miguel-Ángel Salinero-Fort⁶, Jose L del Barrio¹, Martin Romero-Maroto¹,
10 Rodrigo Jiménez-García¹
11

12 ¹Medicine and Surgery, Psychology, Preventive Medicine and Public Health, Medical
13 Microbiology and Immunology, Nursing and Oral Medicine Department. Universidad
14 Rey Juan Carlos. Alcorcón. Comunidad de Madrid. Spain.
15

16 ²Respiratory Care Department, Hospital General Universitario Gregorio Marañón.
17 Comunidad de Madrid. Spain.
18

19 ³Internal Medicine Department. Hospital Universitario Clínico San Carlos. Madrid.
20 Comunidad de Madrid. Spain.
21

22 ⁴Internal Medicine Department. Hospital General Universitario Gregorio Marañón.
23 Madrid. Comunidad de Madrid. Spain.
24

25 ⁵Health Security Agency. Ministry of Health, Social Services and Equality. Madrid.
26 Comunidad de Madrid. Spain.
27

28 ⁶Subdirección General de Investigación Sanitaria, Consejería de Sanidad, Madrid,
29 Spain.
30

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47 Address for correspondence: Rodrigo Jiménez Garcia. Preventive Medicine and Public
48 Health Teaching and Research Unit, Health Sciences Faculty, Rey Juan Carlos
49 University Avda. de Atenas s/n, 28922 Alcorcón, Madrid, Spain. Tel: +34 91 4888853.
50
51
52
53
54 Fax: +34 91 4888848. E-mail: rodrigo.jimenez@urjc.es
55
56
57
58
59
60

- 1
2
3 1 **Key Words:** Type 2 diabetes; Breast cancer; mastectomy; breast-conserving surgery;
4
5 2 complications; hospitalizations
6
7 3 **Word count:** 2,667
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 1 **ABSTRACT**
4

5
6 2 **Objectives:** To assess type 2 diabetes (T2DM) and age-matched non-diabetic women
7
8 3 hospitalized with breast cancer and to compare the type of surgical procedures used,
9
10 4 comorbidities, in-hospital complications (IHC), and in-hospital outcomes. We aimed to
11
12 5 identify factors associated with in-hospital complications in women with T2DM who
13
14 6 underwent breast cancer surgical procedures.

15
16
17 7 **Design:** Retrospective study using National Hospital Discharge Database, 2013–2014.

18
19 8 **Setting:** Spain.

20
21 9 **Participants:** Women who were ≥ 40 years old with a primary diagnosis of breast
22
23 10 cancer and had undergone a surgical procedure. We grouped admissions by T2DM
24
25 11 status. We selected one age-matched control for each T2DM case.

26
27
28 12 **Main outcome measures:** The type of procedure (breast-conserving surgery (BCS) or
29
30 13 mastectomy), clinical characteristics, complications, length of hospital stay and in-
31
32 14 hospital-mortality were analyzed.

33
34
35 15 **Results:** We identified 41,458 admissions (9.23% with T2DM). Overall, and in addition
36
37 16 to the surgical procedure, we found that comorbidity, hypertension and obesity were
38
39 17 more common in patients with T2DM. We detected a higher use of mastectomy in
40
41 18 women with T2DM (44.69% vs. 42.42%) and the greater use of BCS in patients without
42
43 19 T2DM (57.58% vs. 55.31%). Overall, non-infectious complications showed a higher
44
45 20 incidence among women with T2DM (8.08% vs. 6.12%). Among women who had
46
47 21 undergone BCS, IHC were more frequent in those suffering diabetes (6.38% vs. 4.49%),
48
49 22 and were equivalent for those who had received a mastectomy (11.99% vs. 10.04%).
50
51 23 Comorbidity and obesity were significantly associated with a higher risk of IHC in
52
53 24 women with diabetes independent of the procedure that was used.
54
55
56
57
58
59
60

1 **Conclusions:** Women with T2DM who undergo breast cancer surgical procedures have
2 more comorbidity, risk factors and advanced cancer presentation than in similar non-
3 T2DM patients. Mastectomy is more frequently used in diabetic women. Moreover, the
4 procedures in women with T2DM were associated with more IHC. Comorbidity and
5 obesity were strong predictors of IHC in women with T2DM.

6 7 **Strengths and limitations of this study**

- 8 • The strengths of our study lies its large simple size, standardized methodology,
9 and use of age- and province-matched non-T2DM patients to control for the
10 confounding effects of these variables.
- 11 • A limitation is the lack of information on chemotherapy or radiotherapy
12 treatments prior to surgery, which may have affected our outcome variables.
- 13 • We lacked data such as breast cancer characteristics or time since diagnosis.

1 INTRODUCTION

2 Breast cancer is the most common type of cancer in women. [1] Recently, the Global
3 Burden of Disease Cancer Collaboration reported that the incidence of breast cancer
4 between 2005 and 2015 in Western Europe increased by 24%, from 100.6 to 124.7
5 cases per 100,000 individuals. Breast cancer was also the leading cause of cancer-
6 related deaths in women. [1]

7 Breast-conserving surgery (BCS) and mastectomy remains the current therapeutic
8 approach for breast cancer. Recently, the use of BCS has increased and become the
9 primary surgical treatment for breast cancer. [2,3] In Spain, over 80% of women
10 diagnosed with breast cancer underwent surgery, and among these patients, nearly 75%
11 received BCS. [3] However, recent studies have shown an increased number of
12 mastectomies in women candidates for BCS because of the rise of more cosmetically
13 appealing techniques. [4]

14 Recently, a report using the American College of Surgeons National Surgical Quality
15 Improvement Program (NSQIP) database to study 30-day complication rates after breast
16 operations concluded that BCS and mastectomy with implant reconstruction have low
17 overall complication rates. Additionally, BCS in early stage breast cancer was
18 associated with fewer overall early postoperative complications compared with
19 mastectomy [OR 2.8; 95%CI 2.2–3.5, $p < 0.01$]. [5]

20 Diabetes is a predictor associated with postoperative complications in women who
21 undergo surgical procedures for breast cancer. [5-7] In women with early-stage breast
22 cancer, diabetes has been found to be a risk factor for overall postoperative
23 complications (OR 1.8; 95%CI 1.02–3.4, $p = 0.04$). [5] De Blacam et al., using the
24 NSQIP database, reported that independent risk factors for the development of infection

1 of any wound in patients undergoing mastectomy included a high body mass index,
2 smoking, and diabetes. [7]

3 To the best of our knowledge, no previous studies have investigated factors associated
4 with in-hospital complications in women with diabetes undergoing breast cancer-related
5 surgical procedures.

6 Using the Spanish national hospital discharge database for 2013–2014, we aim in this
7 study to i) compare variables between type 2 diabetes (T2DM) and age-matched non-
8 diabetes women hospitalized with breast cancer who underwent a surgical procedure,
9 including the type of surgical procedure used (BCS or mastectomy), patient
10 comorbidities, in-hospital complications and in-hospital outcomes (length of hospital
11 stay and in-hospital mortality); and ii) identify factors associated with in-hospital
12 complications in women with T2DM who underwent breast cancer surgical procedures.

14 **METHODS**

15 We performed a retrospective, observational study using the Spanish National Hospital
16 Discharge Database (*Conjunto Mínimo Básico de Datos*, CMBD), which is managed by
17 the Spanish Ministry of Health, Social Services and Equality (MHSSE) and compiles all
18 public and private hospital data, which covers more than 98% of hospital admissions.
19 [8] The CMBD includes patient variables (sex and date of birth), admission and
20 discharge dates, and up to 14 diagnoses at discharge and up to 20 procedures performed
21 during the hospital stay.

22 We analyzed data collected between January 1, 2013 and December 31, 2014 for
23 women with and without T2DM who were aged 40 and over. In both groups, we
24 selected patients with a primary diagnosis of breast cancer (ICD-9-MC codes: 174.0-
25 174.9) and whose medical procedures included BCS (ICD-9-MC codes: 85.20-85.25)

1 and/or mastectomy (ICD-9-MC codes: 85.41-85.48) in any procedure field of the
2 database. If both types of procedures were recorded, that case was excluded.

3 We identified 41,458 admissions with breast cancer who underwent surgical procedures
4 in 2013 and 2014 in Spain. Among those admissions, 3,882 (9.23%) had T2DM.
5 Patients who underwent breast cancer surgical procedures in the non-diabetes group
6 were selected to create a control group. Cases were matched with controls by age and
7 province of residence; if more than one control was available for a case, the selection
8 was conducted randomly. Ultimately, we identified 3,826 pairs of women.

9 In a second phase, to compare outcomes according to the type of procedure, we repeated
10 the process and selected one non-diabetic woman (matched by age and province of
11 residence) for each of 2,116 T2DM women who underwent BCS. We also selected
12 1,623 matched couples who underwent mastectomy. Clinical characteristics included
13 data on overall comorbidities at the time of diagnosis, which were assessed by
14 calculating the Charlson comorbidity index (CCI) and excluding cancer and diabetes as
15 diseases. [9] We divided patients into three categories: CCI0, which corresponds to
16 patients with no previously recorded disease; CCI1, patients with one disease category;
17 and $CCI \geq 2$, patients with two or more disease categories.

18 We retrieved data about specific comorbidities, including acute myocardial infarction,
19 congestive heart failure, renal disease, stroke/TIA/TEP and vascular disease, as
20 described by Quan et al. and that were applied to ICD-9-CM. [10]

21 Tumor stage was classified as local (within the breast), regional (affecting the lymph
22 nodes—primarily those in the armpit and/or upper arm) or distant (in other parts of the
23 body) according to Escribà et al. using the enhanced ICD-9-CM. [3]

24 Specific risk factors considered in the data analysis included obesity (ICD-9-CM code:
25 278.xx), hypertension (ICD-9-CM codes: 401; 401.0; 401.1; 401.9) and current

1 smoking (ICD-9-CM codes: 305.1;V15.82) recorded during hospitalization for breast
2 cancer in any diagnostic position.

3 Additionally, we specifically recorded the following procedures: sentinel lymph node
4 dissection (ICD-9-CM codes: 40.11; 40.19; 40.23) and axillary lymph node dissection
5 (ICD-9-MC codes: 40.3; 40.50; 40.51).

6 Irrespective of the position at diagnoses or the procedure coding list, we retrieved data
7 about in-hospital “infectious complications,” such as pneumonia (ICD-9-CM codes:
8 997.39,480-488;507.0-507.8), sepsis (ICD-9-CM codes: 995.91, 995.92) and surgical
9 site infection (breast specific infection, ICD-9-CM codes 611.0; postoperative infection,
10 ICD-9-CM codes 998.5-998.59; cellulitis, ICD-9-CM codes 682.2, 682.9;
11 Staphylococcus aureus, ICD-9-CM codes 041.1-041.19; incision/drainage, ICD-9-CM
12 codes 85.0, 85.91. 83.44-83.49, 86.01, 86.04, 86.09, 86.22, 86.28). Additionally, we
13 noted “non-infectious complications” after surgery that included postoperative
14 hemorrhage/hematoma (ICD-9-CM codes 998.11, 998.12), fat necrosis (ICD-9-CM
15 codes 567.82, 611.3), dehiscence (ICD-9-CM codes 875.0, 875.1, 879.0, 879.1, 998.3,
16 998.32) and necrosis (ICD-9-CM codes 998.83).

17 Hospital outcome variables included length of hospital stay (LOHS) and in-hospital
18 mortality (IHM), which was defined as the proportion of patients who died during the
19 admission.

20 **Statistical analysis**

21 A descriptive statistical analysis was performed for all continuous variables and
22 categories by stratifying admissions for breast cancer according to diabetes status.

23 Variables were expressed as proportions, either as the means with standard deviations or
24 medians with interquartile ranges (LOHS). We performed bivariate conditional logistic
25 regression models to compare the prevalence of clinical characteristics, risk factors,

1 comorbidities, procedures, complications and in-hospital outcomes between T2DM
2 patients and controls. The analysis was conducted for the entire sample and stratified
3 according to the procedure type (i.e., BCS or mastectomy).

4 To identify variables associated with in-hospital complications among patients after
5 breast cancer surgical procedures and T2DM, we performed a logistic regression
6 analysis with any complication (infectious or non-infectious) as a binary outcome
7 variable. Finally, we performed two logistic regression analyses to specifically identify
8 variables associated with complications among patients suffering from diabetes who
9 underwent BCS and mastectomy. Variables included in these models were those with
10 significant results in the bivariate analysis and those considered relevant in other
11 investigations. Estimates were described as an odds ratio (OR) with associated 95%
12 confidence intervals.

13 Matching of cases with controls and all statistical analyses were performed using Stata
14 version 10.1 (Stata, College Station, TX, USA). Statistical significance was set at
15 $p < 0.05$ (two-tailed).

16 **Ethical aspects**

17 Data confidentiality was maintained at all times in accordance with Spanish regulations.
18 Given the anonymous and mandatory nature of the dataset, it was not deemed necessary
19 to obtain informed consent. The study protocol was approved by the ethics committee
20 of the Universidad Rey Juan Carlos.

22 **RESULTS**

23 Before matching was conducted, women with T2DM (3,882) were significantly older
24 (70.66 ± 10.24 vs. 60.2 ± 12.71 years; $p < 0.001$) than women without T2DM (37,576).

1
2
3 1 Table 1 shows the characteristics of hospital admissions for breast cancer patients who
4
5 2 underwent a surgical procedure among women with T2DM and age-matched non-
6
7 3 T2DM controls.

8
9
10 4 When we compared women with T2DM with matched controls, we found that patients
11
12 5 with diabetes had more coexisting medical conditions according to the CCI ($p<0.001$).
13
14 6 Specifically, T2DM women had a higher prevalence of vascular disease (8.86% vs.
15
16 7 6.51%), renal disease (4.10% vs. 1.49%), stroke (2.51% vs. 1.73%), congestive heart
17
18 8 failure (2.01% vs. 1.05%) and acute myocardial infarction (0.99% vs. 0.42%).
19
20 9 Additionally, the prevalence of hypertension (65.58% vs. 37.74%) and obesity (13.15%
21
22 10 vs. 3.76%) were higher in T2DM patients.

23
24
25 11 In contrast, we found that a local tumor stage of the disease was more prevalent in non-
26
27 12 T2DM women than in those with T2DM (73.86% vs. 71.33%; $p=0.020$).

28
29
30 13 Regarding the procedures that we analyzed, significant differences ($p=0.04$) were
31
32 14 detected, with a higher use of mastectomy in women with T2DM compared with non-
33
34 15 diabetic women (44.69% vs. 42.42%, $p<0.05$) and a greater use of BCS in patients
35
36 16 without T2DM (57.58% vs. 55.31%).

37
38
39 17 As shown in Table 1, all types of in-hospital complications were more frequent among
40
41 18 women with T2DM (8.89%) than in women without diabetes (6.85%; $p<0.05$). When
42
43 19 the types of complication were analyzed, only non-infectious complications showed
44
45 20 significant differences (8.08% vs. 6.12%).

46
47 21 Median LOHS and IHM values did not differ between diabetic and non-diabetic
48
49 22 women.

50
51
52 23

1 **Table 1.** Clinical characteristics, type of surgical procedure, complications and hospital
 2 outcomes of hospital admissions for breast cancer among women suffering type 2
 3 diabetes and age-matched non-type 2 diabetes controls.

	Both groups (n=7,652)		p-value
Age, mean (SD)	70.66 (10.24)		NA
40-59 years old, n (%)	547 (14.30)		
60-79 years old, n (%)	2435 (63.64)		
≥ 80 years old, n (%)	844 (22.06)		NA
	Diabetes (n=3,826)	No Diabetes (n=3,826)	
CCI0, n (%)	3119 (81.52)	3391(88.63)	
CCI1, n (%)	591 (15.45)	376 (9.83)	
CCI≥2, n (%)	116 (3.03)	59 (1.54)	<0.001
Vascular disease, n (%)	339 (8.86)	249(6.51)	<0.001
Renal disease, n (%)	157 (4.10)	57 (1.49)	<0.001
Stroke/TIA/TEP, n (%)	96 (2.51)	66 (1.73)	0.017
Congestive heart failure, n (%)	77 (2.01)	40 (1.05)	0.001
Acute myocardial infarction, n (%)	38 (0.99)	16 (0.42)	0.003
Obesity, n (%)	503 (13.15)	144 (3.76)	<0.001
Hypertension, n (%)	2509 (65.58)	1444 (37.74)	<0.001
Smoking, n (%)	183 (4.78)	213 (5.57)	0.112
Stage: Local, n(%)	2729 (71.33)	2826 (73.86)	
Stage: Regional, n(%)	986 (25.77)	896 (23.42)	
Stage: Distant, n (%)	111 (2.90)	104 (2.72)	0.020
Breast conservative surgical procedure, n (%)	2116 (55.31)	2203(57.58)	
Breast radical surgical procedure, n (%)	1710 (44.69)	1623 (42.42)	0.040
Infectious complications, n (%)	114 (2.98)	87 (2.27)	0.212
Non infectious complications, n (%)	309 (8.08)	234(6.12)	0.001
All complications (infectious and/or non infectious), n (%)	340 (8.89)	262 (6.85)	0.001
Length of stay, median (IQR)	3 (2-5)	3 (2-5)	0.070
In-hospital mortality, n (%)	6 (0.16)	1 (0.03)	0.097

4 CCI: Charlson Comorbidity Index. IQR: Interquartile range. P value for difference between T2DM
 5 sufferers and matched controls using bivariate conditional logistic regression.

6
 7

1
2
3 1 Table 2 shows the characteristics of hospital admissions after BCS procedures in
4
5 2 women suffering from T2DM and procedure- and age-matched non-T2DM controls.
6
7 3 Women with diabetes who underwent BCS were significantly younger than those who
8
9 4 underwent a mastectomy (68.72 vs. 72.97 years; $p<0.001$).
10
11 5 Among those women who underwent a BSC, those with T2DM had higher frequencies
12
13 6 of comorbidities according to the CCI compared with matched controls ($p<0.001$).
14
15 7 Vascular disease, renal disease, acute myocardial infarction, obesity and hypertension
16
17 8 were significantly more prevalent in patients with diabetes than in matched controls.
18
19 9 As shown in Table 2, we found a significantly lower use of sentinel lymph node
20
21 10 dissection in T2DM patients compared with controls (62.62% vs. 66.18%).
22
23 11 Women with T2DM had a higher prevalence of all in-hospital complications (infectious
24
25 12 and/or non-infectious) compared to those without diabetes (6.38% vs. 4.49%,
26
27 13 respectively, $p=0.006$) and also for non-infectious complications alone (5.77% vs.
28
29 14 4.22%).
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Table 2.** Clinical characteristics, complications and hospital outcomes of hospital
 2 admissions for breast cancer among women suffering type 2 diabetes who underwent a
 3 breast conservative surgical procedure and procedure-age-matched non-type 2 diabetes
 4 controls

	Both groups (n=4,232)		p-value
Age, mean (SD)	68.72 (9.69)		NA
40-59 years old, n (%)	356 (16.82)		
59-79 years old, n (%)	1440 (68.05)		
≥ 80 years old, n (%)	320 (15.12)		NA
	Diabetes (n=2,116)	No Diabetes (n=2,116)	
CCI0, n (%)	1771 (83.70)	1909 (90.24)	
CCI1, n (%)	299 (14.13)	182 (8.62)	
CCI≥2, n (%)	46 (2.17)	24 (1.14)	<0.001
Vascular disease, n(%)	175 (8.27)	112(5.31)	<0.001
Renal disease, n(%)	67 (3.17)	29 (1.36)	<0.001
Acute myocardial infarction, n (%)	25 (1.18)	6 (0.27)	<0.001
Stroke/TIA/TEP, n(%)	37 (1.75)	23 (1.09)	0.066
Congestive heart failure, n(%)	22 (1.04)	15 (0.73)	0.270
Hypertension, n (%)	1387 (65.55)	745 (35.22)	<0.001
Obesity, n (%)	288 (13.61)	82 (3.86)	<0.001
Smoking, n (%)	118 (5.58)	131 (6.17)	0.405
Stage: Local, n(%)	1622 (76.65)	1674 (79.12)	
Stage: Regional, n(%)	459 (21.69)	412 (19.47)	
Stage: Distant, n (%)	35 (1.65)	30 (1.41)	0.145
Sentinel lymph node dissection, n (%)	1325 (62.62)	1400 (66.18)	0.014
Axillary lymph node dissection, n (%)	443 (20.94)	397 (18.75)	0.071
Infectious complications, n (%)	39 (1.84)	25 (1.18)	0.074
Non infectious complications, n(%)	122 (5.77)	89 (4.22)	0.020
All complications (infectious and/or non infectious), n (%)	135 (6.38)	95 (4.49)	0.006
Length of stay, median (IQR)	2 (1-3)	2 (1-3)	0.062
In-hospital mortality, n (%)	2 (0.09)	0 (0.00)	0.149

5 CCI: Charlson Comorbidity Index. IQR: Interquartile range. P value for difference between T2DM
 6 sufferers and matched controls using bivariate conditional logistic regression.

10

1
2
3 1 Results obtained when we compared patients with T2DM who underwent mastectomy
4
5 2 with age-matched controls who received this same procedure are shown in Table 3.
6
7 3 Women with T2DM had more coexisting medical conditions according to the CCI and a
8
9 4 higher prevalence of renal disease, congestive heart failure, obesity and hypertension
10
11 5 than women without diabetes. Additionally, women with T2DM had a higher
12
13 6 prevalence of in-hospital complications (infectious and/or non-infectious) than those
14
15 7 without diabetes (11.99% vs. 10.04%, respectively; $p=0.023$). According to the type of
16
17 8 complications, differences were only significant for non-infectious complications
18
19 9 (10.94% vs. 8.69%; $p=0.029$).
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

10

Table 3. Clinical characteristics, complications and hospital outcomes of hospital admissions for breast cancer among women suffering type 2 diabetes who underwent a mastectomy and procedure-age-matched non-type 2 diabetes controls

	Both groups (n=3,246)		p-value
Age, mean (SD)	72.97 (10.64)		NA
40-59 years old, n (%)	184 (11.34)		
60-79 years old, n (%)	923 (56.87)		
≥ 80 years old, n (%)	516 (31.79)		NA
	Diabetes (n=1,623)	No Diabetes (n=1,623)	
CCI0, n (%)	1279 (78.83)	1403 (86.44)	<0.001
CCI1, n (%)	277 (17.08)	186 (11.46)	
CCI≥2, n (%)	66 (4.09)	34 (2.1)	
Renal disease, n(%)	85(5.26)	27(1.66)	<0.001
Congestive heart failure, n(%)	52 (3.22)	24(1.48)	0.001
Vascular disease, n(%)	156(9.59)	132(8.13)	0.139
Stroke/TIA/TEP, n(%)	56(3.45)	42(2.59)	0.147
Acute myocardial infarction, n (%)	12 (0.76)	10 (0.62)	0.615
Obesity, n (%)	204 (12.57)	59 (3.64)	<0.001
Hypertension, n (%)	1065 (65.61)	668 (41.16)	<0.001
Smoking, n (%)	62 (3.80)	77 (4.74)	0.178
Stage: Local, n(%)	1051 (64.74)	1083 (66.73)	0.433
Stage: Regional, n(%)	500 (30.82)	467 (28.77)	
Stage: Distant, n (%)	72 (4.44)	73 (4.50)	
Sentinel lymph node dissection, n (%)	544 (33.51)	586 (36.11)	0.116
Axillary lymph node dissection, n (%)	199 (12.28)	183 (11.28)	0.368
Infectious complications, n (%)	71 (4.39)	61 (3.76)	0.360
Non infectious complications, n(%)	177(10.94)	141(8.69)	0.029
All complications (infectious and/or non infectious), n (%)	195(11.99)	163 (10.04)	0.023
Length of stay, median (IQR)	4(3-6)	4(3-6)	0.074
In-hospital mortality, n (%)	4(0.23)	1 (0.06)	0.199

CCI: Charlson Comorbidity Index. IQR: Interquartile range. P value for difference between T2DM sufferers and matched controls using bivariate conditional logistic regression.

1
2
3 1 Table 4 shows the results of logistic regression analyses to assess those factors
4
5 2 associated with in-hospital complications in patients with T2DM during hospital
6
7 3 admission for breast cancer who underwent any breast surgical procedures and
8
9 4 specifically according to the type of procedure. Among T2DM women with breast
10
11 5 cancer and after any surgical procedure (i.e., conservative or mastectomy), comorbidity
12
13 6 (OR 1.55, 95%CI 1.29–1.86) and obesity (OR 1.55, 95%CI 1.15–2.08) were the factors
14
15 7 most strongly associated with a higher rate of in-hospital complications. These two
16
17 8 factors also increased the risk of in-hospital complications for women who underwent
18
19 9 BCS or mastectomy.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

10

11

1 **Table 4.** Logistic regression analysis of the factor associated with in-hospital
 2 complications in women with type 2 diabetes during hospital admission for breast
 3 cancer and after any breast surgical procedures and according to the type of surgical
 4 procedure.

		OR (95%CI)
		Any breast cancer surgical procedure (Conservative or mastectomy)
Age groups, years	40-59	1
	60-79	0.98 (0.70-1.38)
	≥ 80	1.17 (0.79-1.72)
CCI, mean		1.55 (1.29-1.86)
Stage	Distant	1.21 (0.98-1.48)
Obesity	Yes	1.55 (1.15-2.08)
		Breast Conservative Surgery
Age groups, years	40-59	1
	60-79	0.79 (0.50-1.26)
	≥ 80	0.92 (0.50-1.67)
CCI, mean		1.71 (1.26-2.33)
Obesity	Yes	1.68 (1.08-2.61)
		Mastectomy
Age groups, years	40-59	1
	60-79	1.12 (0.67-1.87)
	≥ 80	1.21 (0.70-2.08)
CCI, mean		1.43 (1.14-1.80)
Obesity	Yes	1.48 (1.01-2.25)

6 CCI: Charlson Comorbidity Index. OR: Odds Ratio. 95%CI: 95% confidence intervals. Only those
 7 variables that showed a significant association are showed.

8
 9
 10
 11

1 DISCUSSION

2 T2DM is considered to be a common comorbidity that is present in many breast cancer
3 patients and correlates with poor clinical outcomes. [11,12] According to information
4 obtained from the CMBD, compared with nondiabetic counterparts, women with T2DM
5 undergoing breast cancer surgical procedures had more risk factors, comorbidities and
6 advanced cancer presentations.

7 Several studies have reported that the presence of risk factors, such as hypertension and
8 obesity, are common in both diabetes and breast cancer patients. [13,14] A recent meta-
9 analysis that included 82 follow-up studies confirms the associations of obesity with an
10 unfavorable overall and breast cancer survival rate in pre- and post-menopausal breast
11 cancer. [15] Several hypotheses have been proposed to explain the poorer survival
12 outcomes observed with increasing body mass index. [16] Obese patients may undergo
13 less mammographic screening, and increased breast adiposity may delay tumor
14 detection and diagnosis until the tumors grow larger. [17,18] Another possibility is that
15 obese patients were undertreated compared to normal weight patients. [19]

16 In our present study, women with T2DM were significantly more likely to present with
17 advanced-stage breast cancer compared with those women without diabetes. Our
18 findings are consistent with other studies that demonstrated a more advanced stage of
19 breast cancer among women with diabetes. [20, 21] A study conducted in Canada
20 showed that diabetes was associated with more advanced-stage breast cancer, even after
21 accounting for differences in screening mammogram use and other factors. [22] There
22 are several possible explanations for this association, including that mammograms are
23 less sensitive for the detection of early lesions in women with T2DM because of higher
24 rates of obesity. [23] Finally, tumors may progress more rapidly in patients with
25 diabetes, or diabetes may lead to a higher metastatic potential. [24]

1
2
3 1 We observed that mastectomy is more frequently used in diabetic women, which could
4
5 2 be explained by several factors, including higher comorbidity, higher stage disease at
6
7 3 diagnosis, the presence of more biologically aggressive tumors and that diabetes is an
8
9 4 important risk factor for breast cancer recurrence. [3, 24] Kaplan et al. examined 483
10
11 5 breast cancer patients who had undergone a mastectomy that was completed between
12
13 6 1998 and 2010. They concluded that the recurrence of breast cancer was significantly
14
15 7 increased in patients with diabetes (OR, 2.21; 95%CI 1.23–3.96; p=0.008). [25]

16
17 8 As expected, we observed that in-hospital mortality and complication rates in breast
18
19 9 cancer surgery were low. This finding is consistent with de Blacam et al., who found in
20
21 10 a multi-institutional study of patients undergoing mastectomy and BCS reported in the
22
23 11 US that the overall 30-day morbidity rate was 5.6% for all procedures. [7]

24
25
26
27 12 We found that women with T2DM who underwent breast cancer surgical procedures
28
29 13 had a higher frequency of overall in-hospital complications compared with those
30
31 14 women without diabetes. Several studies have reported that diabetes is a risk factor for
32
33 15 surgical site infections after breast operations. [7] A systematic review/meta-analysis
34
35 16 concluded that patients with diabetes were more vulnerable to surgical site infections
36
37 17 after breast cancer surgery (OR 1.88, 95%CI 1.47–2.39). [26]

38
39
40
41 18 In our present study, comorbidity was a strong predictor of in-hospital complications in
42
43 19 women with T2DM who underwent surgical breast cancer-related procedures. Dehale et
44
45 20 al. studied the impact of comorbidity using hospital discharge data from the “Health
46
47 21 Care Utilization Project: Nationwide In-patient Sample” database in women with a
48
49 22 primary diagnosis of breast cancer after undergoing breast surgery. Compared with
50
51 23 patients without a comorbidity, they found that women with a severe (CCI score ≥ 3)
52
53 24 comorbidity were 4.6-times more likely to develop a postoperative complication. [27]

1
2
3 1 Obesity was associated with an increased risk of surgical site infection, in accord with
4
5 2 previous reports. [6] In our present study, obesity was a predictor of IHC in women with
6
7 3 diabetes who underwent BCS and mastectomy. Overweight or obesity have been
8
9 4 associated with higher rates of treatment-related sequelae, such as lymphedema, fatigue
10
11 5 and arthralgia. [28] Helyer et al. concluded that obesity is a risk factor for the
12
13 6 development of postoperative lymphedema in breast cancer patients (OR 1.8; 95%CI,
14
15 7 1.0004–1.165). [29] Excess adiposity may increase the risk of lymphedema by driving
16
17 8 increased inflammation, adding stress to the lymphatic system, or slowing post-surgical
18
19 9 healing times. [30]

20
21
22
23 10 The strengths of our study included its large simple size, standardized methodology, and
24
25 11 use of age- and province-matched non-T2DM patients to control for the confounding
26
27 12 effects of these variables. However, our study had several limitations. First, the database
28
29 13 was designed for administrative rather than research purposes, and conditions such as
30
31 14 infection, hypertension, obesity and smoking may not have been adequately recorded in
32
33 15 the database. [8]

34
35
36 16 Second, the database that we used contained no information about chemotherapy or
37
38 17 radiotherapy treatments prior to surgery, which may have affected our outcome
39
40 18 variables.

41
42
43 19 Finally, we lacked data such as breast cancer characteristics or time since diagnosis.
44
45 20

46 47 21 **CONCLUSIONS**

48
49 22 We conclude that women with T2DM who undergo surgical procedures to treat breast
50
51 23 cancer have more comorbidity, risk factors and advanced cancer presentation than non-
52
53 24 T2DM patients. Mastectomy is more frequently performed in diabetic women.
54
55 25 Moreover, procedures carried out in women with T2DM were associated with more in-
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1 hospital complications. Finally, comorbidity and obesity were strong predictors of in-
- 2 hospital complications in women with T2DM.

For peer review only

1
2
3 **1 ACKNOWLEDGEMENTS**

4
5
6 2 We would like to thank the Spanish Ministry of Health and Social Policy for providing
7
8 3 the records of the CMBD (Conjunto Mínimo Básico de Datos).

9
10
11 **4 CONTRIBUTIONS**

12
13
14 5 Ana López-de-Andres and Rodrigo Jiménez-García participated in the conception and
15
16 6 design, analysis, interpretation, and writing of the article. Valentín Hernández-Barrera
17
18 7 and Isabel Jiménez-Trujillo contributed their statistical expertise and towards
19
20 8 conception and design, interpretation and writing of the article. Javier de Miguel-Díez,
21
22 9 Manuel Méndez-Bailón, José M de Miguel-Yanes, Napoleón Pérez-Farinós, Miguel-
23
24 10 Angel Salinero-Fort, José L del Barrio and Martín Romero-Maroto were involved in the
25
26 11 critical revision of the article, interpretation and design. All authors have seen and
27
28 12 approved the final version.

29
30
31
32
33 **13 COMPETING INTERESTS**

34
35
36 14 The authors declare that they have no competing interests.

37
38
39 **15 DATA SHARING STATEMENT**

40
41 16 "No additional data available"

42
43 **17 FUNDING**

44
45
46 18 This study is part of research funded by the FIS (Fondo de Investigaciones Sanitarias-
47
48 19 Health Research Fund, grant no. PI16/00564, Instituto de Salud Carlos III) co-financed
49
50 20 by the European Union through the Fondo Europeo de Desarrollo Regional (FEDER,
51
52 21 "Una manera de hacer Europa") and by the Grupo de Excelencia Investigadora URJC-
53
54 22 Banco Santander N°30VCP1G103: Investigación traslacional en el proceso de salud -
55
56 23 enfermedad (ITPSE).

1
2
3 **1 REFERENCES**

4 1. Global Burden of Disease Cancer Collaboration. Global, regional, and national
5 cancer incidence, mortality, years of life lost, years lived with disability, and disability-
6 adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the
7 global burden of disease study. *JAMA Oncol* 2017;3(4):524-548.

8 2. Raine R, Wong W, Scholes S, Ashton C, Obichere A, Ambler G. Social variations in
9 access to hospital care for patients with colorectal, breast and lung cancer between 1999
10 and 2006: retrospective analysis of hospital episode statistics. *BMJ* 2010;340:b5479.

11 3. Escribà JM, Pareja L, Esteban L, et al. Trends in the surgical procedures of women
12 with incident breast cancer in Catalonia, Spain, over a 7-year period (2005–2011). *BMC*
13 *Res Notes* 2014; 7:587.

14 4. Chang JM, Kosiorek HE, Dueck AC, et al. Trends in mastectomy and reconstruction
15 for breast cancer; a twelve year experience from a tertiary care center. *Am J Surg*
16 2016;212(6):1201-10.

17 5. Pyfer B, Chatterjee A, Chen L, Nigriny J, Czerniecki B, Tchou J, Fisher C. Early
18 postoperative outcomes in breast conservation surgery versus simple mastectomy with
19 implant reconstruction: a NSQIP analysis of 11,645 patients. *Ann Surg Oncol*
20 2016;23(1):92-8.

21 6. El-Tamer MB, Ward BM, Schiffner T, Neumayer L, Khuri S, Henderson W.
22 Morbidity and mortality following breast cancer surgery in women: national
23 benchmarks for standards of care. *Ann Surg* 2007;245(5):665-71.

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 7. de Blacam C, Ogunleye AA, Momoh AO, et al. High body mass index and smoking
4
5 2 predict morbidity in breast cancer surgery: a multivariate analysis of 26,988 patients
6
7 3 from the national surgical quality improvement program database. *Ann Surg*
8
9 4 2012;255(3):551-5.
10
11
12 5 8. Ministerio de Sanidad, Servicios Sociales e Igualdad. Registro de Altas de los
13
14 6 Hospitales Generales del Sistema Nacional de Salud. CMBD. Available from
15
16 7 <https://www.msssi.gob.es/estadEstudios/estadisticas/cmbd.htm>. Accessed 15 February
17
18 8 2017.
19
20
21 9 9. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
22
23 10 prognostic comorbidity in longitudinal studies: development and validation. *J Chronic*
24
25 11 *Dis* 1987;40:373-83.
26
27
28 12 10. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining
29
30 13 comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care* 2005;43:1130-
31
32 14 9.
33
34
35 15 11. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. The impact of
36
37 16 diabetes on survival following breast cancer. *Breast Cancer Res Treat*
38
39 17 2008;109(2):389-95.
40
41
42 18 12. Pears KS, Barone BB, Snyder CF, et al. Diabetes mellitus and breast cancer
43
44 19 outcomes: a systematic review and meta-analysis. *J Clin Oncol* 2011; 29(1):40-6.
45
46
47 20 13. Patterson RE, Flatt SW, Saquib N, et al. Medical comorbidities predict mortality in
48
49 21 women with a history of early stage breast cancer. *Breast Cancer Res Treat*
50
51 22 2010;122(3):859-65.
52
53
54
55
56
57
58
59
60

- 1
2
3 1 14. Jousheghany F, Phelps J, Crook T, Hakkak R. Relationship between level of
4
5 2 HbA1C and breast cancer. *BBA Clin* 2016;6:45-8.
6
7
8 3 15. Chan DS, Vieira AR, Aune D, et al. Body mass index and survival in women with
9
10 4 breast cancer-systematic literature review and meta-analysis of 82 follow-up studies.
11
12 5 *Ann Oncol* 2014;25(10):1901-14.
13
14
15 6 16. Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN, Giordano SH. Obesity,
16
17 7 diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients.
18
19 8 *Ann Oncol* 2013;24(10):2506-14.
20
21
22
23 9 17. Chang VW, Asch DA, Werner RM. Quality of care among obese patients. *JAMA*
24
25 10 2010;303:1274–81.
26
27
28 11 18. Maruthur NM, Bolen S, Brancati FL, et al. Obesity and mammography: a systematic
29
30 12 review and meta-analysis. *J Gen Intern Med* 2009;24:665–677.
31
32
33 13 19. Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving
34
35 14 breast cancer chemotherapy. *Arch Intern Med* 2005;165:1267–1273.
36
37
38 15 20. Srokowski TP, Fang S, Hortobagyi GN, Giordano SH. Impact of diabetes mellitus
39
40 16 on complications and outcomes of adjuvant chemotherapy in older patients with breast
41
42 17 cancer. *J Clin Oncol* 2009;27(13):2170–2176.
43
44
45
46 18 21. van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, Dercksen MW,
47
48 19 Coebergh JW, Haak HR. Less aggressive treatment and worse overall survival in cancer
49
50 20 patients with diabetes: a large population based analysis. *Int J Cancer* 2007;
51
52 21 120(9):1986–1992.
53
54
55
56
57
58
59
60

- 1
2
3 1 22. Lipscombe LL, Fischer HD, Austin PC, et al. The association between diabetes and
4 breast cancer stage at diagnosis: a population-based study. *Breast Cancer Res Treat*
5 2015;150(3):613-620.
6
7
8
9
10 4 23. Kerlikowske K, Walker R, Miglioretti DL, Desai A, Ballard-Barbash R, Buist DS.
11 Obesity, mammography use and accuracy, and advanced breast cancer risk. *J Natl*
12 *Cancer Inst* 2008;100(23):1724–1733.
13
14
15
16
17
18 7 24. Godsland IF. Insulin resistance and hyperinsulinaemia in the development and
19 progression of cancer. *Clin Sci* 2010;118(5):315–332.
20
21
22
23 9 25. Kaplan MA, Pekkoyay Z, Kucukoner M, et al. Type 2 diabetes mellitus and
24 prognosis in early stage breast cancer women. *Med Oncol* 2012;29(3):1576-1580.
25
26
27
28 11 26. Xue DQ, Qian C, Yang L, Wang XF. Risk factors for surgical site infections after
29 breast surgery: a systematic review and meta-analysis. *Eur J Surg Oncol*
30 2012;38(5):375-381.
31
32
33
34
35
36 14 27. Dehal A, Abbas A, Johna S. Comorbidity and outcomes after surgery among women
37 with breast cancer: analysis of nationwide in-patient sample database. *Breast Cancer*
38 *Res Treat* 2013;139(2):469-476.
39
40
41
42
43 17 28. Ridner S, Dietrich M, Stewart R, Armer J. Body mass index and breast cancer
44 treatment-related lymphedema. *Support Care Cancer* 2011;19:853–857.
45
46
47
48 19 29. Helyer LK, Varnic M, Le LW, Leong W, McCready D. Obesity is a risk factor for
49 developing postoperative lymphedema in breast cancer patients. *Breast J*
50 2010;16(1):48-54.
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 30. Ahmed RL, Schmitz KH, Prizment AE, Folsom AR. Risk factors for lymphedema
2 in breast cancer survivors, the Iowa Women’s Health Study. *Breast Cancer Res Treat*
3 2011;130(3):981–991.

For peer review only

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-4
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5,6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5,6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6,7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-8
Bias	9	Describe any efforts to address potential sources of bias	6-8
Study size	10	Explain how the study size was arrived at	6-8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8,9
		(b) Describe any methods used to examine subgroups and interactions	8,9
		(c) Explain how missing data were addressed	
		(d) If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	9-17
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest	9-17
Outcome data	15*	Report numbers of outcome events or summary measures	9-17
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9-17
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	18-20
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	18-20
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	18-20
Generalisability	21	Discuss the generalisability (external validity) of the study results	20,21
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	22

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

The effect of Type 2 diabetes on in-hospital complications among women undergoing breast cancer surgical procedures. A retrospective study using the Spanish National Hospital Discharge Database, 2013–2014.



Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-017676.R1
Article Type:	Research
Date Submitted by the Author:	06-Sep-2017
Complete List of Authors:	Lopez-de-Andres, Ana ; Universidad Rey Juan Carlos, Preventive Medicine and Public Health Teaching and Research Unit. Jimenez-Trujillo, Isabel ; Universidad Rey Juan Carlos, Preventive Medicine and Public Health Teaching and Research Unit Hernandez-Barrera, Valentin; Universidad Rey Juan Carlos, Preventive Medicine and Public Health Teaching and Research Unit de Miguel-Diez, Javier; Hospital General Universitario Gregorio Marañón, Mendez-Bailon, Manuel; Hospital Clinico Universitario San Carlos, Internal Medicine Department de Miguel-Yanes, Jose; Hospital General Universitario Gregorio Marañón, Internal Medicine Department Perez-Farinos, Napoleon; Ministry of Health, Social Services and Equality, Health Security Agency SALINERO-FORT, MIGUEL; Servicio Madrileño de Salud, Gerencia de Atención Primaria del Barrio, Jose; Universidad Rey Juan Carlos Romero-Maroto, Martin; Universidad Rey Juan Carlos Jimenez-Garcia, Rodrigo; Univ Rey Juan Carlos,
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Diabetes and endocrinology
Keywords:	Type 2 diabetes, Breast cancer, mastectomy, breast-conserving surgery, complications, hospitalizations

SCHOLARONE™
Manuscripts

1
2
3 1 **The effect of Type 2 diabetes on in-hospital complications among women undergoing**
4 **breast cancer surgical procedures. A retrospective study using the Spanish National**
5 **Hospital Discharge Database, 2013–2014.**
6
7

8 Ana López-de-Andrés¹, Isabel Jiménez-Trujillo¹, Valentín Hernández-Barrera¹, Javier de
9 Miguel-Díez², Manuel Méndez-Bailón³, José M de Miguel-Yanes⁴, Napoleón Pérez-Farínós⁵,
10 Miguel-Ángel Salinero-Fort⁶, Jose L del Barrio¹, Martin Romero-Maroto¹, Rodrigo Jiménez-
11 García¹

12
13
14
15
16
17 ¹Department of Medicine and Surgery, Psychology, Preventive Medicine and Public Health,
18 Medical Microbiology and Immunology, Nursing and Oral Medicine. Universidad Rey Juan
19 Carlos. Alcorcón, Comunidad de Madrid, Spain.
20

21
22
23 ²Respiratory Care Department, Hospital General Universitario Gregorio Marañón, Comunidad
24 de Madrid, Spain.
25

26
27 ³Internal Medicine Department. Hospital Universitario Clínico San Carlos, Madrid, Comunidad
28 de Madrid, Spain.
29

30
31 ⁴Internal Medicine Department. Hospital General Universitario Gregorio Marañón, Madrid,
32 Comunidad de Madrid, Spain.
33

34
35 ⁵Health Security Agency. Ministry of Health, Social Services and Equality, Madrid, Comunidad
36 de Madrid, Spain.
37

38
39 ⁶Subdirección General de Investigación Sanitaria, Consejería de Sanidad, Madrid, Spain.
40

41
42
43
44 Address for correspondence: Rodrigo Jiménez Garcia. Preventive Medicine and Public Health
45 Teaching and Research Unit, Health Sciences Faculty, Rey Juan Carlos University Avda. de
46 Atenas s/n, 28922 Alcorcón, Madrid, Spain. Tel: +34 91 4888853. Fax: +34 91 4888848. E-
47 mail: rodrigo.jimenez@urjc.es
48
49

50
51
52 **Key Words:** Type 2 diabetes; breast cancer; mastectomy; breast-conserving surgery;
53 complications; hospitalizations
54

55
56 **Word count: 3447**
57
58
59
60

1
2
3 **1 ABSTRACT**

4 **2 Objectives:** To compare the type of surgical procedures used, comorbidities, in-hospital
5 complications (IHC), and in-hospital outcomes between women with type 2 diabetes (T2DM)
6 and age-matched women without diabetes who were hospitalized with breast cancer. In addition
7 we sought to identify factors associated with IHC in women with T2DM who had undergone
8 surgical procedures for breast cancer.

9 **7 Design:** Retrospective study using the National Hospital Discharge Database, 2013–2014.

10 **8 Setting:** Spain.

11 **9 Participants:** Women who were ≥ 40 years old with a primary diagnosis of breast cancer and
12 who had undergone a surgical procedure. We grouped admissions by T2DM status. We selected
13 one matched control for each T2DM case.

14 **12 Main outcome measures:** The type of procedure (breast-conserving surgery (BCS) or
15 mastectomy), clinical characteristics, complications, length of hospital stay and in-hospital-
16 mortality.

17 **15 Results:** We identified 41,458 admissions (9.23% with T2DM). Overall, and in addition to the
18 surgical procedure, we found that comorbidity, hypertension and obesity were more common
19 among patients with T2DM. We also detected a higher incidence of mastectomy in women with
20 T2DM (44.69% vs. 42.42%) and a greater rate of BCS in patients without T2DM (57.58% vs.
21 55.31%). Overall, non-infectious complications were more common among women with T2DM
22 (6.40% vs. 4.56%). Among women who had undergone BCS or a mastectomy, IHC were more
23 frequent among diabetics (5.57% vs. 3.04% and 10.60% vs. 8.24%, respectively). Comorbidity
24 was significantly associated with a higher risk of IHC in women with diabetes, independent of
25 the specific procedure used.

26 **24 Conclusions:** Women with T2DM who undergo surgical breast cancer procedures have more
27 comorbidity, risk factors and advanced cancer presentations than matched patients without
28 T2DM. Mastectomies are more common in women with T2DM. Moreover, the procedures
29 among women with T2DM were associated with greater IHC. Comorbidity was a strong
30 predictor of IHC in women with T2DM.

1

2 **Strengths and limitations of this study**

- 3 • The strengths of our study include the large sample size, the standardized methodology,
4 and the use of age- province- surgical procedure and stage-matched women without
5 T2DM to control for the confounding effects of these variables.
- 6 • A limitation of this study is the lack of information on chemotherapy or radiotherapy
7 treatments prior to surgery, which may have affected our outcome variables.
- 8 • We lacked data such as specific breast cancer characteristics or accurate time frames
9 since diagnosis.
- 10 • The effect of obesity on in-hospital complications must be interpreted with caution for
11 the possible existence of a codification bias.

12

1 INTRODUCTION

2 Breast cancer is the most common type of cancer in women. [1] Recently, the Global Burden of
3 Disease Cancer Collaboration reported that the incidence of breast cancer between 2005 and
4 2015 in Western Europe increased by 24%, from 100.6 to 124.7 cases per 100,000 individuals.

5 Breast cancer was also the leading cause of cancer-related deaths in women. [1]

6 Breast-conserving surgery (BCS) and mastectomy still represent the current therapeutic
7 approach for breast cancer. Recently, the use of BCS has increased and become the primary
8 surgical treatment for breast cancer. [2,3] In Spain, over 80% of women diagnosed with breast
9 cancer underwent surgery and, among these patients, nearly 75% received BCS. [3] However,
10 recent studies have shown an increased number of mastectomies in women who are candidates
11 for BCS because of the rise of more cosmetically appealing techniques. [4]

12 The Spanish Health Care System is public and offers universal coverage with no out-of-pocket
13 expenses for patients.

14 Recently, a report using the American College of Surgeons National Surgical Quality
15 Improvement Program (NSQIP) database to study 30-day complication rates after breast
16 operations concluded that, overall, BCS and mastectomy with implant reconstruction have low
17 complication rates. Additionally, BCS in early stage breast cancer was associated with fewer
18 overall early postoperative complications when compared with mastectomy [OR 2.8; 95%CI
19 2.2–3.5, $p<0.01$]. [5]

20 Diabetes is a predictor associated with postoperative complications in women who undergo
21 surgical procedures for breast cancer. [5-7] In women with early-stage breast cancer, diabetes
22 has been found to be a risk factor for overall postoperative complications (OR 1.8; 95%CI 1.02–
23 3.4, $p=0.04$). [5] De Blacam et al., using the NSQIP database, reported that independent risk
24 factors for the development of an infection of any surgical wound caused by a mastectomy
25 included a high body mass index, smoking, and diabetes. [7]

26 To the best of our knowledge, no previous studies have investigated factors associated with in-
27 hospital complications among women with diabetes undergoing breast cancer-related surgical
28 procedures.

1 hospital uses this discharge report and any additional information required by the hospital
2 databases to complete the SNHDD. The database uses the International Classification of
3 Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) for coding.

4 The Spanish Ministry of Health conducts regular audits to assess the accuracy of the SNHDD
5 [8, 9]. Several studies have been conducted to assess the validity of the SNHDD for several
6 conditions, including diabetes. [10-13]

7 We analyzed data collected between January 1, 2013 and December 31, 2014 for women with
8 and without T2DM who were aged over 40 years old. In both groups, we selected patients with
9 a primary diagnosis of breast cancer (ICD-9-MC codes: 174.0-174.9) and whose medical
10 procedures included BCS (ICD-9-MC codes: 85.20-85.25) and/or mastectomy (ICD-9-MC
11 codes: 85.41-85.48) in any procedure field of the database. If both types of procedures were
12 recorded, that case was excluded (n=137).

13 We identified 41,458 admissions with breast cancer who had undergone surgical procedures in
14 2013 and 2014 in Spain. Among those admissions, 3,882 (9.23%) had T2DM. Patients who
15 underwent surgical breast cancer procedures in the non-diabetes group were selected to create a
16 control group. Cases were matched with controls by age and province of residence (n=50); if
17 more than one control was available for a case, the selection was conducted randomly.
18 Ultimately, we identified 3,826 pairs of women (98.6 % of cases matched).

19 In the second phase, we repeated the process and selected women without diabetes matched by
20 age, province of residence, type of procedure and stage. Therefore, we matched 1,938 T2DM
21 women who underwent BCS and 1,480 who underwent mastectomy (88% of cases matched).
22 Clinical characteristics included data on overall comorbidities at the time of diagnosis, which
23 were assessed by calculating the Charlson comorbidity index (CCI) and excluding both cancer
24 and diabetes as diseases. [14] We divided patients into three categories: CCI0, as in those
25 patients with no previously recorded disease; CCI1, patients with one disease category; and
26 $CCI \geq 2$, patients with two or more disease categories.

1 We retrieved data concerning specific comorbidities, including acute myocardial infarction,
2 congestive heart failure, renal disease, stroke/TIA/TEP and vascular disease, as described by
3 Quan et al. and that were applied to ICD-9-CM. [15]

4 The tumor stage was classified as local (within the breast), regional (affecting the lymph
5 nodes—primarily those in the armpit and/or upper arm) or distant (in other parts of the body)
6 according to Escribà et al. using the enhanced ICD-9-CM. [3]

7 Specific risk factors considered in the data analysis included obesity (ICD-9-CM code: 278.xx),
8 hypertension (ICD-9-CM codes: 401; 401.0; 401.1; 401.9) and current smoking (ICD-9-CM
9 codes: 305.1;V15.82) recorded during hospitalization for breast cancer in any diagnostic
10 position.

11 Additionally, we specifically recorded the following procedures: sentinel lymph node dissection
12 (ICD-9-CM codes: 40.11; 40.19; 40.23) and axillary lymph node dissection (ICD-9-CM codes:
13 40.3; 40.50; 40.51).

14 Irrespective of the position at diagnosis or the procedure coding list, we retrieved data regarding
15 in-hospital “infectious complications,” such as pneumonia (ICD-9-CM codes: 997.39,480-
16 488;507.0-507.8), sepsis (ICD-9-CM codes: 995.91, 995.92) and surgical site infection (breast
17 specific infection, ICD-9-CM codes 611.0; postoperative infection, ICD-9-CM codes 998.5-
18 998.59; cellulitis, ICD-9-CM codes 682.2, 682.9; Staphylococcus aureus, ICD-9-CM codes
19 041.1-041.19; incision/drainage, ICD-9-CM codes 85.0, 85.91, 83.44-83.49, 86.01, 86.04,
20 86.09, 86.22, 86.28). Additionally, we noted “non-infectious complications” after surgery,
21 which included postoperative hemorrhage/hematoma (ICD-9-CM codes 998.11, 998.12), fat
22 necrosis (ICD-9-CM codes 567.82, 611.3), dehiscence (ICD-9-CM codes 875.0, 875.1, 879.0,
23 879.1, 998.3, 998.32) and necrosis (ICD-9-CM codes 998.83).

24 Hospital outcome variables included the length of hospital stay (LOHS) and in-hospital
25 mortality (IHM), the latter being defined as the percentage of patients who died during the
26 admission.

27 **Statistical analysis**

1 A descriptive statistical analysis was performed for all continuous variables and categories by
2 stratifying admissions for breast cancer according to diabetes status. Variables were expressed
3 as proportions, either as the means with standard deviations or medians with interquartile ranges
4 (LOHS). We performed bivariate conditional logistic regression models to compare the
5 prevalence of clinical characteristics, risk factors, comorbidities, procedures, complications and
6 in-hospital outcomes between T2DM patients and controls. The analysis was conducted for the
7 entire sample and stratified according to the procedure type (i.e., BCS or mastectomy).

8 To identify variables associated with in-hospital complications among patients after breast
9 cancer surgical procedures and T2DM, we performed a logistic regression analysis with any
10 complication (infectious or non-infectious) as a binary outcome variable. Finally, we performed
11 two logistic regression analyses to specifically identify variables associated with complications
12 among patients suffering from diabetes who underwent BCS and mastectomy. The variables
13 included in these models were those with significant results in the bivariate analysis ($p < 0.05$)
14 and those considered relevant in other investigations. The variables included in these models
15 were, age, CCI, stage and obesity. The remaining variables were not significant in the bivariate
16 analysis.

17 Estimates were described as the odds ratio (OR) with associated 95% confidence intervals.

18 The matching of cases with controls and all statistical analyses were performed using Stata
19 version 10.1 (Stata, College Station, TX, USA). Statistical significance was set at $p < 0.05$ (two-
20 tailed).

21 **Ethical aspects**

22 Data confidentiality was maintained at all times, in accordance with Spanish law. Given the
23 anonymous and mandatory nature of the dataset, the requirement for informed consent was
24 deemed unnecessary. The study protocol was approved by the ethics committee of the Rey Juan
25 Carlos University.

27 **RESULTS**

1
2
3 1 Before matching was conducted, women with T2DM (3,882) were significantly older
4
5 2 (70.66±10.24 vs. 60.2±12.71 years; $p<0.001$) than women without T2DM (37,576).

6
7 3 Regarding the procedures that we analyzed, when we compared women with T2DM with
8
9 4 matched controls by age and province of residence, significant differences ($p=0.04$) were
10
11 5 detected, with a higher incidence of mastectomy in women with T2DM compared with those
12
13 6 without diabetes (44.69% vs. 42.42%, $p<0.05$) and a greater rate of BCS in patients without
14
15 7 T2DM (57.58% vs. 55.31%).

16
17 8 In contrast, we found that the local tumor stage of the disease was more prevalent in women
18
19 9 without T2DM than in those with T2DM (73.86% vs. 71.33%; $p=0.020$).

20
21 10 Table 1 shows the characteristics of hospital admissions for breast cancer patients who
22
23 11 underwent a surgical procedure and who underwent BCS procedures and mastectomy among
24
25 12 women with T2DM and age-matched controls without T2DM.

26
27 13 When we compared women with T2DM with matched controls, by age, province of residence
28
29 14 and tumor stage, we found that patients with diabetes had more coexisting medical conditions
30
31 15 according to the CCI ($p<0.001$). Specifically, T2DM women had a higher prevalence of
32
33 16 vascular disease (8.81% vs. 6.61%), renal disease (4.13% vs. 1.40%), stroke (2.40% vs. 1.61%),
34
35 17 congestive heart failure (1.93% vs. 0.61%) and acute myocardial infarction (0.97% vs. 0.53%).
36
37 18 Additionally, the prevalence of hypertension (65.54% vs. 36.22%) and obesity (13.17% vs.
38
39 19 3.63%) was higher in T2DM patients.

40
41 20 As shown in Table 1, all types of in-hospital complications were more frequent among women
42
43 21 with T2DM (7.72%) than in women without diabetes (5.30%; $p=0.003$). When the types of
44
45 22 complication were analyzed, only non-infectious complications showed significant differences
46
47 23 (6.40% vs. 4.56%).

48
49 24 Median LOHS and IHM values did not differ between women with and without diabetes.

50
51 25 As can be seen in Table 1, women with diabetes who underwent BCS were significantly
52
53 26 younger than those who underwent a mastectomy (68.18 vs. 72.71 years; $p<0.001$).

54
55 27 Among women who underwent a BSC, those with T2DM had higher frequencies of
56
57 28 comorbidities according to the CCI, when compared with matched controls ($p<0.001$). Vascular
58
59

1 disease, renal disease, acute myocardial infarction, obesity and hypertension were significantly
2 more prevalent in patients with diabetes than in matched controls. We found a significantly
3 lower rate of sentinel lymph node dissection in T2DM patients compared with controls (61.09%
4 vs. 64.86%; $p=0.032$).

5 Women with T2DM who underwent a BSC had a higher prevalence of all in-hospital
6 complications (infectious and/or non-infectious) compared to those without diabetes (5.57% vs.
7 3.04%, respectively, $p=0.008$) and also for non-infectious complications alone (4.80% vs.
8 2.73%).

9 Women with T2DM who underwent mastectomy had more coexisting medical conditions
10 according to the CCI and a higher prevalence of vascular disease, renal disease, congestive heart
11 failure, obesity and hypertension than women without diabetes. Additionally, women with
12 T2DM had a higher prevalence of in-hospital complications (infectious and/or non-infectious)
13 than those without diabetes (10.60% vs. 8.24%, respectively; $p=0.029$). According to the type of
14 complications, differences were only significant for non-infectious complications (8.51% vs.
15 6.96%; $p=0.032$).

16 Table 2 shows the results of logistic regression analyses to assess those factors associated with
17 in-hospital complications in patients with T2DM during hospital admission for breast cancer
18 who underwent any breast surgical procedures and, more specifically, according to the type of
19 procedure. Among T2DM women with breast cancer and after any surgical procedure (i.e.,
20 conservative or mastectomy), comorbidity (vs. no comorbidities, OR 1.72, 95%CI 1.30-2.27 for
21 one comorbidity; OR 2.55, 95%CI 1.55-4.17 for two or more comorbidities) and obesity (OR
22 1.54, 95%CI 1.14–2.07) were the factors most strongly associated with a higher rate of in-
23 hospital complications. These two factors also increased the risk of in-hospital complications for
24 women who underwent BCS. However, among those who underwent mastectomy, only
25 comorbidity was associated with a higher rate of in-hospital complications.

26

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2 **DISCUSSION**

3 T2DM is considered to be a common comorbidity that is present in many breast cancer patients,
4 correlating with poor clinical outcomes. [16,17] According to information obtained from the
5 SNHDD, compared with nondiabetic counterparts, women with T2DM undergoing surgical
6 breast cancer procedures have more risk factors, comorbidities and advanced cancer
7 presentations.

8 Several studies have reported that the presence of risk factors, such as hypertension and obesity,
9 are common in both patients with diabetes and those with breast cancer. [18,19]

10 However, in our study population, the prevalence of obesity is very low among women with
11 diabetes, which is possibly a consequence of under-recording this condition. Previous studies
12 conducted in Spain and other countries have also found an under-reporting of obesity in
13 administrative data. [20-23] These authors suggest the following possible reasons to explain the
14 low rates of obesity in administrative data: i) obesity is not explicitly mentioned in physician
15 reports; ii) people who codify may not record obesity owing to time constraints when
16 performing data abstraction; iii) when time for coding is limited, coders tend to include severe
17 conditions but not risk factors and; iv) the diagnosis of obesity is often not based on the BMI,
18 but rather on the subjective observation made by the clinician, which means that more severe
19 obesity is over-codified [21-23] Furthermore, as described earlier, a possible differential
20 information bias may occur and thus the misclassification of obesity may be related to the
21 presence of diabetes. Thus, ICD codes for obesity may be more commonly assigned to patients
22 suffering from other comorbidities (including diabetes) or postoperative complications. This
23 suggests a greater association between obesity and adverse events than what is obtained based
24 on the BMI calculations. [21, 23] As a result, any association between obesity and the presence
25 of in-hospital complications must be interpreted with caution.

26 In our current study, women with T2DM were significantly more likely to suffer from
27 advanced-stage breast cancer when compared with women without diabetes. Our findings are
28 consistent with other studies demonstrating a more advanced stage of breast cancer among

1 women with diabetes. [24, 25] A study conducted in Canada showed that diabetes was
2 associated with more advanced-stage breast cancer, even after accounting for differences in
3 screening mammogram use and other factors. [26] There are several possible explanations for
4 this association, including the fact that mammograms are less sensitive for the detection of early
5 lesions in women with T2DM because of higher rates of obesity. [27] Finally, tumors may
6 progress more rapidly in patients with diabetes, or diabetes may lead to a higher metastatic
7 potential. [28]

8 We observed that mastectomies are performed more frequently on diabetic women, which could
9 be explained by several factors, including higher comorbidity, higher stage disease at diagnosis,
10 the presence of more biologically aggressive tumors and the fact that diabetes is a major risk
11 factor in breast cancer recurrence. [3, 28] Kaplan et al. examined 483 breast cancer patients who
12 had undergone a mastectomy between 1998 and 2010. They concluded that the recurrence of
13 breast cancer was significantly increased in patients with diabetes (OR, 2.21; 95%CI 1.23–3.96;
14 $p=0.008$). [29]

15 As expected, we observed that in-hospital mortality and complication rates in breast cancer
16 surgery were low. This finding is consistent with de Blacam et al., who, in a multi-institutional
17 study of patients undergoing mastectomy and BCS in the US, found that the overall 30-day
18 morbidity rate was 5.6% for all procedures. [7]

19 We found that women with T2DM who underwent breast cancer surgical procedures had a
20 higher frequency of overall in-hospital complications compared with women without diabetes.
21 Several studies have reported that diabetes is a risk factor for surgical site infections after breast
22 operations. [7] A systematic review/meta-analysis concluded that patients with diabetes were
23 more vulnerable to surgical site infections after breast cancer surgery (OR 1.88, 95%CI 1.47–
24 2.39). [30]

25 In this study, comorbidity was a strong predictor of in-hospital complications in women with
26 T2DM who underwent surgical breast cancer-related procedures. Dehale et al. studied the
27 impact of comorbidity using hospital discharge data from the “Health Care Utilization Project:
28 Nationwide In-patient Sample” database in women with a primary diagnosis of breast cancer

1
2
3 1 after undergoing breast surgery. They found that women with a severe (CCI score ≥ 3)
4
5 2 comorbidity were 4.6-times more likely to develop a postoperative complication when
6
7 3 compared with patients without a comorbidity. [31]

8
9 4 In our present study, obesity was a predictor of IHC in women with diabetes who underwent
10
11 5 BCS. Being overweight or obese has been associated with higher rates of treatment-related
12
13 6 sequelae, such as lymphedema, fatigue and arthralgia. [32] Helyer et al. concluded that obesity
14
15 7 is a risk factor for the development of postoperative lymphedema in breast cancer patients (OR
16
17 8 1.8; 95%CI, 1.0004–1.165). [33] Excess adiposity may increase the risk of lymphedema by
18
19 9 driving increased inflammation, adding stress to the lymphatic system, or slowing post-surgical
20
21 10 healing times. [34] However, as commented previously, the uncertainty regarding the validity of
22
23 11 the obesity codification in the SNHDD requires caution when interpreting this result.

24
25 12 The strengths of our study included its large simple size, the standardized methodology, and use
26
27 13 of age- and province-matched non-T2DM patients to control for the confounding effects of
28
29 14 these variables. However, our study has several limitations. First, the validity of the T2DM must
30
31 15 be discussed. In Spain, the diagnosis of type 2 diabetes is mainly performed in primary care
32
33 16 centers. [35] Even if patients are diagnosed during hospitalization they are sent to their primary
34
35 17 care center for the follow up and necessary medical prescriptions. A study conducted to validate
36
37 18 the diabetes mellitus diagnosis in the computerized clinical records of primary health care,
38
39 19 taking the 2003 American Diabetes Association Consensus Statement as the gold standard,
40
41 20 found that the agreement was very high ($\kappa=0.990$), with a specificity of 99.49% and a sensitivity
42
43 21 of 99.53%. [35] The validity of the diabetes diagnosis in the SNHDD has been assessed in two
44
45 22 previous studies, revealing a sensitivity of 55% and 63.7% and a specificity of approximately
46
47 23 97%. [10,11]

48
49 24 The only moderate sensitivity found means that an important proportion of T2DM patients do
50
51 25 not have this diagnosis codified in their discharge report. On the other hand, the very high
52
53 26 specificity means that most patients without a T2DM diagnosis do not really have this disease;
54
55 27 therefore, we think that the effect of this misclassification on our design is possibly very small.
56
57 28 Furthermore, as commented previously regarding obesity, the database was designed for
58
59
60

1 administrative rather than research purposes, therefore conditions such as infection,
2 hypertension and smoking may not have been adequately recorded in the database. [8, 10, 11]
3 Second, unfortunately the ICD 9 does not include information regarding whether a condition is
4 part of the patient's past medical history or if this appeared during the hospitalization.
5 Therefore, it is possible that a patient may first be diagnosed with diabetes or any other
6 condition studied during the hospitalization. However, we think that this possibly affects a very
7 small proportion of patients and thus the effect on our results would be minimal.
8 Third, the database that we used contained no information about chemotherapy or radiotherapy
9 treatments prior to surgery, which may have affected our outcome variables.
10 Forth, we lacked data such as breast cancer characteristics or the time span since diagnosis.
11 Finally, other relevant variables such as laboratory results, BMI, medical treatments (e.g.
12 glucose lowering drugs, insulin or antibiotics), patients who have undergone a prosthetic
13 reconstruction and the eventual use of an acellular dermal matrix are not included in the
14 SNHDD.

16 CONCLUSIONS

17 We conclude that women with T2DM who undergo surgical procedures to treat breast cancer
18 have more comorbidities, risk factors and a more advanced cancer presentation than women
19 without T2DM. Mastectomies are more frequently performed in diabetic women. Moreover,
20 procedures carried out in women with T2DM were associated with greater in-hospital
21 complications. Finally, comorbidity was a strong predictor of in-hospital complications in
22 women with T2DM.

1
2
3 **1 ACKNOWLEDGEMENTS**

4
5 2 We would like to thank the Spanish Ministry of Health and Social Policy for providing the
6
7 3 records of the SNHDD (Conjunto Mínimo Básico de Datos).

8
9 **4 CONTRIBUTIONS**

10
11 5 Ana López-de-Andres and Rodrigo Jiménez-García participated in the conception and design,
12
13 6 analysis, interpretation, and writing of the manuscript. Valentín Hernández-Barrera and Isabel
14
15 7 Jiménez-Trujillo contributed their statistical expertise and towards conception and design,
16
17 8 interpretation and writing of the manuscript. Javier de Miguel-Díez, Manuel Méndez-Bailón,
18
19 9 José M de Miguel-Yanes, Napoleón Pérez-Farinós, Miguel-Angel Salinero-Fort, José L del
20
21 10 Barrio and Martín Romero-Maroto were involved in the critical revision of the manuscript, as
22
23 11 well as the interpretation and design. All authors have seen and approved the final version.

24
25 **12 COMPETING INTERESTS**

26
27 13 The authors declare that they have no competing interests.

28
29 **14 DATA SHARING STATEMENT**

30
31 15 "No additional data available"

32
33 **16 FUNDING**

34
35 17 This study is part of research funded by the FIS (Fondo de Investigaciones Sanitarias-Health
36
37 18 Research Fund, grants no. PI13/00118 and PI16/00564, Instituto de Salud Carlos III) co-
38
39 19 financed by the European Union through the Fondo Europeo de Desarrollo Regional (FEDER,
40
41 20 "Una manera de hacer Europa") and by the Grupo de Excelencia Investigadora URJC-Banco
42
43 21 Santander N°30VCPIGI03: Investigación traslacional en el proceso de salud - enfermedad
44
45 22 (ITPSE).
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **1 REFERENCES**

- 4 1. Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer
5 incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-
6 years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease
7 study. *JAMA Oncol* 2017;3(4):524-548.
- 8 2. Raine R, Wong W, Scholes S, et al. Social variations in access to hospital care for patients
9 with colorectal, breast and lung cancer between 1999 and 2006: retrospective analysis of
10 hospital episode statistics. *BMJ* 2010;340:b5479.
- 11 3. Escribà JM, Pareja L, Esteban L, et al. Trends in the surgical procedures of women with
12 incident breast cancer in Catalonia, Spain, over a 7-year period (2005–2011). *BMC Res Notes*
13 2014; 7:587.
- 14 4. Chang JM, Kosiorek HE, Dueck AC, et al. Trends in mastectomy and reconstruction for
15 breast cancer; a twelve year experience from a tertiary care center. *Am J Surg*
16 2016;212(6):1201-10.
- 17 5. Pyfer B, Chatterjee A, Chen L, et al. Early postoperative outcomes in breast conservation
18 surgery versus simple mastectomy with implant reconstruction: a NSQIP analysis of 11,645
19 patients. *Ann Surg Oncol* 2016;23(1):92-8.
- 20 6. El-Tamer MB, Ward BM, Schiffner T, et al. Morbidity and mortality following breast cancer
21 surgery in women: national benchmarks for standards of care. *Ann Surg* 2007;245(5):665-71.
- 22 7. de Blacam C, Ogunleye AA, Momoh AO, et al. High body mass index and smoking predict
23 morbidity in breast cancer surgery: a multivariate analysis of 26,988 patients from the national
24 surgical quality improvement program database. *Ann Surg* 2012;255(3):551-5.
- 25 8. Ministerio de Sanidad, Servicios Sociales e Igualdad. Registro de Altas de los Hospitales
26 Generales del Sistema Nacional de Salud. CMBD. Available from
27 <https://www.msssi.gob.es/estadEstudios/estadisticas/cmbdhome.htm>. Accessed 30 August 2017.
- 28 9. Estudio de las comorbilidades que componen el índice de Elixhauser. Análisis de prevalencia
y fiabilidad en los registros del CMBD estatal de hospitalización Available from
<http://icmbd.es/docs/informe-comorbilidades-1.pdf> Accessed 30 August 2017.

- 1
2
3 1 10. Ribera A, Marsal JR, Ferreira-González I, Cascant P, et al. Predicting in-hospital mortality
4 with coronary bypass surgery using hospital discharge data: comparison with a prospective
5 observational study. *Rev Esp Cardiol* 2008; 61(8):843-852.
6
7
8 4 11. Rodrigo-Rincón I, Martín-Vizcaíno MP, Tirapu-León B, et al. Usefulness of administrative
9 databases for risk adjustment of adverse events in surgical patients. *Cir Esp*. 2016;94(3):165-74.
10
11 6 12. Calle JE, Saturno PJ, Parra P, et al. Quality of the information contained in the minimum
12 basic data set: Results from an evaluation in eight hospitals. *Eur J Epidemiol*. 2000; 16: 1073-80
13
14 8 13. Hernández Medrano I, Guillán M, Masjuan J, et al. Reliability of the minimum basic dataset
15 for diagnoses of cerebrovascular disease. *Neurologia*. 2017;32(2):74-80.
16
17 10 14. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic
18 comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373-
19 83.
20
21 13 15. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in
22 ICD-9-CM and ICD-10 administrative data. *Med Care* 2005;43:1130-9.
23
24 15 16. Lipscombe LL, Goodwin PJ, Zinman B, et al. The impact of diabetes on survival following
25 breast cancer. *Breast Cancer Res Treat* 2008;109(2):389-95.
26
27 17 17. Peairs KS, Barone BB, Snyder CF, et al. Diabetes mellitus and breast cancer outcomes: a
28 systematic review and meta-analysis. *J Clin Oncol* 2011; 29(1):40-6.
29
30 18 18. Patterson RE, Flatt SW, Saquib N, et al. Medical comorbidities predict mortality in women
31 with a history of early stage breast cancer. *Breast Cancer Res Treat* 2010;122(3):859-65.
32
33 21 19. Jousheghany F, Phelps J, Crook T, et al. Relationship between level of HbA1C and breast
34 cancer. *BBA Clin* 2016;6:45-8.
35
36 23 20. Sánchez-Muñoz LA. Nutritional status, heart failure and minimum basic data set. *Rev Esp*
37 *Cardiol (Engl Ed)*. 2012 Jun;65(6):583.
38
39 24 21. Martín BJ, Chen G, Graham M, et al. Coding of obesity in administrative hospital discharge
40 abstract data: accuracy and impact for future research studies. *BMC Health Serv Res*. 2014 Feb
41 13;14:70.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 22. Lujic S, Watson DE, Randall DA, et al. Variation in the recording of common health
4 conditions in routine hospital data: study using linked survey and administrative data in New
5 South Wales, Australia. *BMJ Open*. 2014 Sep 3;4(9):e005768.
6
7
8
9 4 23. McLynn RP, Geddes BJ, Cui JJ, et al. Inaccuracies in ICD Coding for Obesity Would be
10 Expected to Bias Administrative Database Spine Studies Toward Overestimating the Impact of
11 Obesity on Perioperative Adverse Outcomes. *Spine (Phila Pa 1976)*. 2017 Aug 1. doi:
12 10.1097/BRS.0000000000002356.
13
14
15
16
17 8 24. Srokowski TP, Fang S, Hortobagyi GN, et al. Impact of diabetes mellitus on complications
18 and outcomes of adjuvant chemotherapy in older patients with breast cancer. *J Clin Oncol*
19 2009;27(13):2170–2176.
20
21
22
23 11 25. van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, et al. Less aggressive treatment
24 and worse overall survival in cancer patients with diabetes: a large population based analysis.
25 *Int J Cancer* 2007; 120(9):1986–1992.
26
27
28
29 14 26. Lipscombe LL, Fischer HD, Austin PC, et al. The association between diabetes and breast
30 cancer stage at diagnosis: a population-based study. *Breast Cancer Res Treat* 2015;150(3):613-
31 620.
32
33
34
35 17 27. Kerlikowske K, Walker R, Miglioretti DL, et al. Obesity, mammography use and accuracy,
36 and advanced breast cancer risk. *J Natl Cancer Inst* 2008;100(23):1724–1733.
37
38
39 19 28. Godsland IF. Insulin resistance and hyperinsulinaemia in the development and progression
40 of cancer. *Clin Sci* 2010;118(5):315–332.
41
42
43 21 29. Kaplan MA, Pekkoley Z, Kucukoner M, et al. Type 2 diabetes mellitus and prognosis in
44 early stage breast cancer women. *Med Oncol* 2012;29(3):1576-1580.
45
46
47 23 30. Xue DQ, Qian C, Yang L, et al. Risk factors for surgical site infections after breast surgery:
48 a systematic review and meta-analysis. *Eur J Surg Oncol* 2012;38(5):375-381.
49
50
51 25 31. Dehal A, Abbas A, Johna S. Comorbidity and outcomes after surgery among women with
52 breast cancer: analysis of nationwide in-patient sample database. *Breast Cancer Res Treat*
53 2013;139(2):469-476.
54
55
56
57
58
59
60

- 1
2
3 1 32. Ridner S, Dietrich M, Stewart R, et al. Body mass index and breast cancer treatment-related
4 lymphedema. *Support Care Cancer* 2011;19:853–857.
5
6
7 33. Helyer LK, Varnic M, Le LW, et al. Obesity is a risk factor for developing postoperative
8 lymphedema in breast cancer patients. *Breast J* 2010;16(1):48-54.
9
10
11 34. Ahmed RL, Schmitz KH, Prizment AE, Folsom AR. Risk factors for lymphedema in breast
12 cancer survivors, the Iowa Women’s Health Study. *Breast Cancer Res Treat* 2011;130(3):981–
13 991.
14
15
16
17 35. de Burgos-Lunar C, Salinero-Fort MA, Cárdenas-Valladolid J, et al. Validation of diabetes
18 mellitus and hypertension diagnosis in computerized medical records in primary health care.
19
20
21 BMC Med Res Methodol. 2011;11:146.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Clinical characteristics, complications and hospital outcomes of hospital admissions for breast cancer and according to type of surgical procedure among women suffering type 2 diabetes and matched women without type 2 diabetes.

	Total (n=6,836)			Breast conservative surgery (n=,3876)			Mastectomy (n=2,960)		
	Diabetes (n=3,418)	No diabetes (n=3,418)	p-value	Diabetes (n=1,938)	No diabetes (n=1,938)	p-value	Diabetes (n=1,480)	No diabetes (n=1,480)	p-value
Age, mean (SD)	70.14(10.22)	70.14(10.22)	NA	68.18(9.53)	68.18(9.53)	NA	72.71(10.51)	72.71(10.51)	NA
40-59 years old, n (%)	522(15.27)	522(15.27)	NA	343(17.7)	343(17.7)	NA	179(12.09)	179(12.09)	NA
60-79 years old, n (%)	2187(63.98)	2187(63.98)		1335(68.89)	1335(68.89)		852(57.57)	852(57.57)	
≥ 80 years old, n (%)	709(20.74)	709(20.74)		260(13.42)	260(13.42)		449(30.34)	449(30.34)	
Stage: Local, n (%)	2590(75.78)	2590(75.78)	NA	1560(80.5)	1560(80.5)	NA	1030(69.59)	1030(69.59)	NA
Stage: Regional, n (%)	799(23.38)	799(23.38)		371(19.14)	371(19.14)		428(28.92)	428(28.92)	
Stage: Distant, n (%)	29(0.85)	29(0.85)		7(0.36)	7(0.36)		22(1.49)	22(1.49)	
CCIO, n (%)	2798(81.86)	3050(89.23)	<0.001	1627(83.95)	1763(90.97)	<0.001	1171(79.12)	1287(86.96)	<0.001
CCI1, n (%)	522(15.27)	324(9.48)		274(14.14)	155(8)		248(16.76)	169(11.42)	
CCI≥2, n (%)	98(2.87)	44(1.29)		37(1.91)	20(1.03)		61(4.12)	24(1.62)	
Vascular disease, n (%)	301(8.81)	226(6.61)	<0.001	159(8.2)	119(6.14)	0.011	142(9.59)	107(7.23)	0.019
Renal disease, n (%)	141(4.13)	48(1.40)	<0.001	61(3.15)	24(1.24)	<0.001	80(5.41)	24(1.62)	<0.001
Stroke/TIA/TEP, n (%)	82(2.40)	55(1.61)	0.020	31(1.60)	22(1.14)	0.201	51(3.45)	33(2.23)	0.051
Congestive heart failure, n (%)	66(1.93)	21(0.61)	<0.001	21(1.08)	9(0.46)	0.020	45(3.04)	12(0.81)	<0.001
Acute myocardial infarction, n (%)	33(0.97)	18(0.53)	0.039	21(1.08)	7(0.36)	0.012	12(0.81)	11(0.74)	0.835
Obesity, n (%)	450(13.17)	124(3.63)	<0.001	267(13.78)	70(3.61)	<0.001	183(12.36)	54(3.65)	<0.001
Hypertension, n (%)	2240(65.54)	1238(36.22)	<0.001	1267(65.38)	654(33.75)	<0.001	973(65.74)	584(39.46)	<0.001
Smoking, n (%)	166(4.86)	185(5.41)	0.288	111(5.73)	121(6.24)	0.488	55(3.72)	64(4.32)	0.393
Sentinel lymph node dissection, n (%)	1697(49.65)	1795(52.52)	0.092	1184(61.09)	1257(64.86)	0.032	513(34.66)	538(36.35)	0.332
Axillary lymph node dissection, n (%)	560(16.38)	551(16.12)	0.747	375(19.35)	382(19.71)	0.752	185(12.5)	169(11.42)	0.349
Infectious complications, n (%)	95(2.78)	76(2.22)	0.138	35(1.81)	22(1.14)	0.088	60(4.05)	54(3.65)	0.560
Non infectious complications, n(%)	219(6.40)	156(4.56)	0.004	93(4.80)	53(2.73)	0.015	126(8.51)	103(6.96)	0.032
All complications (infectious and/or non infectious), n (%)	264(7.72)	181(5.30)	0.003	107(5.57)	59(3.04)	0.008	157(10.60)	122(8.24)	0.029
Length of stay, median (IQR)	3(2-5)	3(2-5)	0.070	2(1-3)	2(1-3)	0.065	4(3-6)	4(3-6)	0.062
In-hospital mortality, n (%)	5(0.15)	2(0.06)	0.277	2(0.1)	1(0.05)	0.571	3(0.2)	1(0.07)	0.341

CCI: Charlson Comorbidity Index. IQR: Interquartile range. P value for difference between T2DM sufferers and matched controls using bivariate conditional logistic regression. Matching was conducted by age, province of residence, type of surgical procedure and stage.

1 **Table 2.** Logistic regression analysis of the factor associated with in-hospital complications in women with type 2 diabetes during
 2 hospital admission for breast cancer according to the type of surgical procedure.

		Any breast cancer surgical procedure (Conservative or mastectomy) OR (95%CI)	Breast Conservative Surgery OR (95%CI)	Mastectomy OR (95%CI)
Age groups, years	40-59	1	1	1
	60-79	0.98 (0.70-1.37)	0.79 (0.50-1.26)	1.12 (0.67-1.86)
	≥ 80	1.16 (0.79-1.71)	0.92 (0.50-1.67)	1.22 (0.71-2.10)
CCI	0	1	1	1
	1	1.72(1.30-2.27)	1.75(1.12-2.71)	1.64(1.14-2.35)
	≥2	2.55(1.55-4.17)	3.33(1.48-7.48)	2.10(1.13-3.91)
Stage	Local	1	1	1
	Regional/distant	1.21 (0.98-1.48)	1.08(0.74-1.55)	1.19(0.93-1.52)
Obesity	Yes	1.54 (1.14-2.07)	1.68 (1.07-2.60)	1.46(0.98-2.19)

3 CCI: Charlson Comorbidity Index. OR: Odds Ratio. 95%CI: 95% confidence intervals. All variables included in the models are shown.

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-4
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5,6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5,6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6,7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-8
Bias	9	Describe any efforts to address potential sources of bias	6-8
Study size	10	Explain how the study size was arrived at	6-8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8,9
		(b) Describe any methods used to examine subgroups and interactions	8,9
		(c) Explain how missing data were addressed	
		(d) If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	9-17
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest	9-17
Outcome data	15*	Report numbers of outcome events or summary measures	9-17
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9-17
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	18-20
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	18-20
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	18-20
Generalisability	21	Discuss the generalisability (external validity) of the study results	20,21
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	22

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

The association of Type 2 diabetes with in-hospital complications among women undergoing breast cancer surgical procedures. A retrospective study using the Spanish National Hospital Discharge Database, 2013–2014.



Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-017676.R2
Article Type:	Research
Date Submitted by the Author:	06-Oct-2017
Complete List of Authors:	Lopez-de-Andres, Ana ; Universidad Rey Juan Carlos, Preventive Medicine and Public Health Teaching and Research Unit. Jimenez-Trujillo, Isabel ; Universidad Rey Juan Carlos, Preventive Medicine and Public Health Teaching and Research Unit Hernandez-Barrera, Valentin; Universidad Rey Juan Carlos, Preventive Medicine and Public Health Teaching and Research Unit de Miguel-Diez, Javier; Hospital General Universitario Gregorio Marañón, Mendez-Bailon, Manuel; Hospital Clinico Universitario San Carlos, Internal Medicine Department de Miguel-Yanes, Jose; Hospital General Universitario Gregorio Marañón, Internal Medicine Department Perez-Farinos, Napoleon; Ministry of Health, Social Services and Equality, Health Security Agency SALINERO-FORT, MIGUEL; Servicio Madrileño de Salud, Gerencia de Atención Primaria del Barrio, Jose; Universidad Rey Juan Carlos Romero-Maroto, Martin; Universidad Rey Juan Carlos Jimenez-Garcia, Rodrigo; Univ Rey Juan Carlos,
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Diabetes and endocrinology
Keywords:	Type 2 diabetes, Breast cancer, mastectomy, breast-conserving surgery, complications, hospitalizations

SCHOLARONE™
Manuscripts

1
2
3 1 **The association of Type 2 diabetes with in-hospital complications among women**
4
5 2 **undergoing breast cancer surgical procedures. A retrospective study using the Spanish**
6
7 3 **National Hospital Discharge Database, 2013–2014.**

8
9 4 Ana López-de-Andrés¹, Isabel Jiménez-Trujillo¹, Valentín Hernández-Barrera¹, Javier de
10
11 5 Miguel-Díez², Manuel Méndez-Bailón³, José M de Miguel-Yanes⁴, Napoleón Pérez-Farinós⁵,
12
13 6 Miguel-Ángel Salinero-Fort⁶, Jose L del Barrio¹, Martin Romero-Maroto¹, Rodrigo Jiménez-
14
15 7 García¹

16
17 8 ¹Department of Medicine and Surgery, Psychology, Preventive Medicine and Public Health,
18
19 9 Medical Microbiology and Immunology, Nursing and Oral Medicine. Universidad Rey Juan
20
21 10 Carlos. Alcorcón, Comunidad de Madrid, Spain.

22
23 11 ²Respiratory Care Department, Hospital General Universitario Gregorio Marañón, Comunidad
24
25 12 de Madrid, Spain.

26
27 13 ³Internal Medicine Department. Hospital Universitario Clínico San Carlos, Madrid, Comunidad
28
29 14 de Madrid, Spain.

30
31 15 ⁴Internal Medicine Department. Hospital General Universitario Gregorio Marañón, Madrid,
32
33 16 Comunidad de Madrid, Spain.

34
35 17 ⁵Health Security Agency. Ministry of Health, Social Services and Equality, Madrid, Comunidad
36
37 18 de Madrid, Spain.

38
39 19 ⁶Subdirección General de Investigación Sanitaria, Consejería de Sanidad, Madrid, Spain.
40
41 20

42
43 21 Address for correspondence: Rodrigo Jiménez Garcia. Preventive Medicine and Public Health
44
45 22 Teaching and Research Unit, Health Sciences Faculty, Rey Juan Carlos University Avda. de
46
47 23 Atenas s/n, 28922 Alcorcón, Madrid, Spain. Tel: +34 91 4888853. Fax: +34 91 4888848. E-
48
49 24 mail: rodrigo.jimenez@urjc.es

50
51 25 **Key Words:** Type 2 diabetes; breast cancer; mastectomy; breast-conserving surgery;
52
53 26 complications; hospitalizations

54
55 27 **Word count: 3467**
56
57
58
59
60

1
2
3 **1 ABSTRACT**

4 **2 Objectives:** To compare the type of surgical procedures used, comorbidities, in-hospital
5 complications (IHC), and in-hospital outcomes between women with type 2 diabetes (T2DM)
6 and age-matched women without diabetes who were hospitalized with breast cancer. In addition
7 we sought to identify factors associated with IHC in women with T2DM who had undergone
8 surgical procedures for breast cancer.

9 **7 Design:** Retrospective study using the National Hospital Discharge Database, 2013–2014.

10 **8 Setting:** Spain.

11 **9 Participants:** Women who were ≥ 40 years old with a primary diagnosis of breast cancer and
12 who had undergone a surgical procedure. We grouped admissions by T2DM status. We selected
13 one matched control for each T2DM case.

14 **12 Main outcome measures:** The type of procedure (breast-conserving surgery (BCS) or
15 mastectomy), clinical characteristics, complications, length of hospital stay and in-hospital-
16 mortality.

17 **15 Results:** We identified 41,458 admissions (9.23% with T2DM). Overall, and in addition to the
18 surgical procedure, we found that comorbidity, hypertension and obesity were more common
19 among patients with T2DM. We also detected a higher incidence of mastectomy in women with
20 T2DM (44.69% vs. 42.42%) and a greater rate of BCS in patients without T2DM (57.58% vs.
21 55.31%). Overall, non-infectious complications were more common among women with T2DM
22 (6.40% vs. 4.56%). Among women who had undergone BCS or a mastectomy, IHC were more
23 frequent among diabetics (5.57% vs. 3.04% and 10.60% vs. 8.24%, respectively). Comorbidity
24 was significantly associated with a higher risk of IHC in women with diabetes, independent of
25 the specific procedure used.

26 **24 Conclusions:** Women with T2DM who undergo surgical breast cancer procedures have more
27 comorbidity, risk factors and advanced cancer presentations than matched patients without
28 T2DM. Mastectomies are more common in women with T2DM. Moreover, the procedures
29 among women with T2DM were associated with greater IHC. Comorbidity was a strong
30 predictor of IHC in women with T2DM.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- The strengths of our study include the large sample size, the standardized methodology, and the use of age- province- surgical procedure and stage-matched women without T2DM to control for the confounding effects of these variables.
- A limitation of this study is the lack of information on chemotherapy or radiotherapy treatments prior to surgery, which may have affected our outcome variables.
- We lacked data such as specific breast cancer characteristics or accurate time frames since diagnosis.
- The association of obesity on in-hospital complications must be interpreted with caution for the possible existence of a codification bias.

1 INTRODUCTION

2 Breast cancer is the most common type of cancer in women. [1] Recently, the Global Burden of
3 Disease Cancer Collaboration reported that the incidence of breast cancer between 2005 and
4 2015 in Western Europe increased by 24%, from 100.6 to 124.7 cases per 100,000 individuals.

5 Breast cancer was also the leading cause of cancer-related deaths in women. [1]

6 Breast-conserving surgery (BCS) and mastectomy still represent the current therapeutic
7 approach for breast cancer. Recently, the use of BCS has increased and become the primary
8 surgical treatment for breast cancer. [2,3] In Spain, over 80% of women diagnosed with breast
9 cancer underwent surgery and, among these patients, nearly 75% received BCS. [3] However,
10 recent studies have shown an increased number of mastectomies in women who are candidates
11 for BCS because of the rise of more cosmetically appealing techniques. [4]

12 The Spanish Health Care System is public and offers universal coverage with no out-of-pocket
13 expenses for patients.

14 Recently, a report using the American College of Surgeons National Surgical Quality
15 Improvement Program (NSQIP) database to study 30-day complication rates after breast
16 operations concluded that, overall, BCS and mastectomy with implant reconstruction have low
17 complication rates. Additionally, BCS in early stage breast cancer was associated with fewer
18 overall early postoperative complications when compared with mastectomy [OR 2.8; 95%CI
19 2.2–3.5, $p<0.01$]. [5]

20 Diabetes is a predictor associated with postoperative complications in women who undergo
21 surgical procedures for breast cancer. [5-7] In women with early-stage breast cancer, diabetes
22 has been found to be a risk factor for overall postoperative complications (OR 1.8; 95%CI 1.02–
23 3.4, $p=0.04$). [5] De Blacam et al., using the NSQIP database, reported that independent risk
24 factors for the development of an infection of any surgical wound caused by a mastectomy
25 included a high body mass index, smoking, and diabetes. [7]

26 To the best of our knowledge, no previous studies have investigated factors associated with in-
27 hospital complications among women with diabetes undergoing breast cancer-related surgical
28 procedures.

1 hospital uses this discharge report and any additional information required by the hospital
2 databases to complete the SNHDD. The database uses the International Classification of
3 Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) for coding.

4 The Spanish Ministry of Health conducts regular audits to assess the accuracy of the SNHDD
5 [8, 9]. Several studies have been conducted to assess the validity of the SNHDD for several
6 conditions, including diabetes. [10-13]

7 In Spain, the diagnosis of type 2 diabetes is mainly performed in primary care centers using the
8 American Diabetes Association (ADA) Consensus Statement. [14] Even if patients are
9 diagnosed during hospitalization they are sent to their primary care center for the follow up and
10 necessary medical prescriptions.

11 We analyzed data collected between January 1, 2013 and December 31, 2014 for women with
12 and without T2DM who were aged over 40 years old. In both groups, we selected patients with
13 a primary diagnosis of breast cancer (ICD-9-MC codes: 174.0-174.9) and whose medical
14 procedures included BCS (ICD-9-MC codes: 85.20-85.25) and/or mastectomy (ICD-9-MC
15 codes: 85.41-85.48) in any procedure field of the database. If both types of procedures were
16 recorded, that case was excluded (n=137).

17 We identified 41,458 admissions with breast cancer who had undergone surgical procedures in
18 2013 and 2014 in Spain. Among those admissions, 3,882 (9.23%) had T2DM. Patients who
19 underwent surgical breast cancer procedures in the non-diabetes group were selected to create a
20 control group. Cases were matched with controls by age and province of residence (n=50); if
21 more than one control was available for a case, the selection was conducted randomly.
22 Ultimately, we identified 3,826 pairs of women (98.6 % of cases matched).

23 In the second phase, we repeated the process and selected women without diabetes matched by
24 age, province of residence, type of procedure and stage. Therefore, we matched 1,938 T2DM
25 women who underwent BCS and 1,480 who underwent mastectomy (88% of cases matched).
26 Clinical characteristics included data on overall comorbidities at the time of diagnosis, which
27 were assessed by calculating the Charlson comorbidity index (CCI) and excluding both cancer
28 and diabetes as diseases. [15] We divided patients into three categories: CCI0, as in those

1 patients with no previously recorded disease; CCI1, patients with one disease category; and
2 CCI \geq 2, patients with two or more disease categories.

3 We retrieved data concerning specific comorbidities, including acute myocardial infarction,
4 congestive heart failure, renal disease, stroke/TIA/TEP and vascular disease, as described by
5 Quan et al. and that were applied to ICD-9-CM. [16]

6 The tumor stage was classified as local (within the breast), regional (affecting the lymph
7 nodes—primarily those in the armpit and/or upper arm) or distant (in other parts of the body)
8 according to Escribà et al. using the enhanced ICD-9-CM. [3]

9 Specific risk factors considered in the data analysis included obesity (ICD-9-CM code: 278.xx),
10 hypertension (ICD-9-CM codes: 401; 401.0; 401.1; 401.9) and current smoking (ICD-9-CM
11 codes: 305.1;V15.82) recorded during hospitalization for breast cancer in any diagnostic
12 position.

13 Additionally, we specifically recorded the following procedures: sentinel lymph node dissection
14 (ICD-9-CM codes: 40.11; 40.19; 40.23) and axillary lymph node dissection (ICD-9-CM codes:
15 40.3; 40.50; 40.51).

16 Irrespective of the position at diagnosis or the procedure coding list, we retrieved data regarding
17 in-hospital “infectious complications,” such as pneumonia (ICD-9-CM codes: 997.39,480-
18 488;507.0-507.8), sepsis (ICD-9-CM codes: 995.91, 995.92) and surgical site infection (breast
19 specific infection, ICD-9-CM codes 611.0; postoperative infection, ICD-9-CM codes 998.5-
20 998.59; cellulitis, ICD-9-CM codes 682.2, 682.9; Staphylococcus aureus, ICD-9-CM codes
21 041.1-041.19; incision/drainage, ICD-9-CM codes 85.0, 85.91. 83.44-83.49, 86.01, 86.04,
22 86.09, 86.22, 86.28). Additionally, we noted “non-infectious complications” after surgery,
23 which included postoperative hemorrhage/hematoma (ICD-9-CM codes 998.11, 998.12), fat
24 necrosis (ICD-9-CM codes 567.82, 611.3), dehiscence (ICD-9-CM codes 875.0, 875.1, 879.0,
25 879.1, 998.3, 998.32) and necrosis (ICD-9-CM codes 998.83).

26 Hospital outcome variables included the length of hospital stay (LOHS) and in-hospital
27 mortality (IHM), the latter being defined as the percentage of patients who died during the
28 admission.

1 **Statistical analysis**

2 A descriptive statistical analysis was performed for all continuous variables and categories by
3 stratifying admissions for breast cancer according to diabetes status. Variables were expressed
4 as proportions, either as the means with standard deviations or medians with interquartile ranges
5 (LOHS). We performed bivariate conditional logistic regression models to compare the
6 prevalence of clinical characteristics, risk factors, comorbidities, procedures, complications and
7 in-hospital outcomes between T2DM patients and controls. The analysis was conducted for the
8 entire sample and stratified according to the procedure type (i.e., BCS or mastectomy).

9 To identify variables associated with in-hospital complications among patients after breast
10 cancer surgical procedures and T2DM, we performed a logistic regression analysis with any
11 complication (infectious or non-infectious) as a binary outcome variable. Finally, we performed
12 two logistic regression analyses to specifically identify variables associated with complications
13 among patients suffering from diabetes who underwent BCS and mastectomy. The variables
14 included in these models were those with significant results in the bivariate analysis ($p < 0.05$)
15 and those considered relevant in other investigations. The variables included in these models
16 were, age, CCI, stage and obesity. The remaining variables were not significant in the bivariate
17 analysis.

18 Estimates were described as the odds ratio (OR) with associated 95% confidence intervals.

19 The matching of cases with controls and all statistical analyses were performed using Stata
20 version 10.1 (Stata, College Station, TX, USA). Statistical significance was set at $p < 0.05$ (two-
21 tailed).

22 **Ethical aspects**

23 Data confidentiality was maintained at all times, in accordance with Spanish law. Given the
24 anonymous and mandatory nature of the dataset, the requirement for informed consent was
25 deemed unnecessary. The study protocol was approved by the ethics committee of the Rey Juan
26 Carlos University.

28 **RESULTS**

1
2
3 1 Before matching was conducted, women with T2DM (3,882) were significantly older
4
5 2 (70.66±10.24 vs. 60.2±12.71 years; $p<0.001$) than women without T2DM (37,576).

6
7 3 Regarding the procedures that we analyzed, when we compared women with T2DM with
8
9 4 matched controls by age and province of residence, significant differences ($p=0.04$) were
10
11 5 detected, with a higher incidence of mastectomy in women with T2DM compared with those
12
13 6 without diabetes (44.69% vs. 42.42%, $p<0.05$) and a greater rate of BCS in patients without
14
15 7 T2DM (57.58% vs. 55.31%).

16
17 8 In contrast, we found that the local tumor stage of the disease was more prevalent in women
18
19 9 without T2DM than in those with T2DM (73.86% vs. 71.33%; $p=0.020$).

20
21 10 Table 1 shows the characteristics of hospital admissions for breast cancer patients who
22
23 11 underwent a surgical procedure and who underwent BCS procedures and mastectomy among
24
25 12 women with T2DM and age-matched controls without T2DM.

26
27 13 When we compared women with T2DM with matched controls, by age, province of residence
28
29 14 and tumor stage, we found that patients with diabetes had more coexisting medical conditions
30
31 15 according to the CCI ($p<0.001$). Specifically, T2DM women had a higher prevalence of
32
33 16 vascular disease (8.81% vs. 6.61%), renal disease (4.13% vs. 1.40%), stroke (2.40% vs. 1.61%),
34
35 17 congestive heart failure (1.93% vs. 0.61%) and acute myocardial infarction (0.97% vs. 0.53%).
36
37 18 Additionally, the prevalence of hypertension (65.54% vs. 36.22%) and obesity (13.17% vs.
38
39 19 3.63%) was higher in T2DM patients.

40
41 20 As shown in Table 1, all types of in-hospital complications were more frequent among women
42
43 21 with T2DM (7.72%) than in women without diabetes (5.30%; $p=0.003$). When the types of
44
45 22 complication were analyzed, only non-infectious complications showed significant differences
46
47 23 (6.40% vs. 4.56%).

48
49 24 Median LOHS and IHM values did not differ between women with and without diabetes.

50
51 25 As can be seen in Table 1, women with diabetes who underwent BCS were significantly
52
53 26 younger than those who underwent a mastectomy (68.18 vs. 72.71 years; $p<0.001$).

54
55 27 Among women who underwent a BSC, those with T2DM had higher frequencies of
56
57 28 comorbidities according to the CCI, when compared with matched controls ($p<0.001$). Vascular
58
59

1 disease, renal disease, acute myocardial infarction, obesity and hypertension were significantly
2 more prevalent in patients with diabetes than in matched controls. We found a significantly
3 lower rate of sentinel lymph node dissection in T2DM patients compared with controls (61.09%
4 vs. 64.86%; $p=0.032$).

5 Women with T2DM who underwent a BSC had a higher prevalence of all in-hospital
6 complications (infectious and/or non-infectious) compared to those without diabetes (5.57% vs.
7 3.04%, respectively, $p=0.008$) and also for non-infectious complications alone (4.80% vs.
8 2.73%).

9 Women with T2DM who underwent mastectomy had more coexisting medical conditions
10 according to the CCI and a higher prevalence of vascular disease, renal disease, congestive heart
11 failure, obesity and hypertension than women without diabetes. Additionally, women with
12 T2DM had a higher prevalence of in-hospital complications (infectious and/or non-infectious)
13 than those without diabetes (10.60% vs. 8.24%, respectively; $p=0.029$). According to the type of
14 complications, differences were only significant for non-infectious complications (8.51% vs.
15 6.96%; $p=0.032$).

16 Table 2 shows the results of logistic regression analyses to assess those factors associated with
17 in-hospital complications in patients with T2DM during hospital admission for breast cancer
18 who underwent any breast surgical procedures and, more specifically, according to the type of
19 procedure. Among T2DM women with breast cancer and after any surgical procedure (i.e.,
20 conservative or mastectomy), comorbidity (vs. no comorbidities, OR 1.72, 95%CI 1.30-2.27 for
21 one comorbidity; OR 2.55, 95%CI 1.55-4.17 for two or more comorbidities) and obesity (OR
22 1.54, 95%CI 1.14–2.07) were the factors most strongly associated with a higher rate of in-
23 hospital complications. These two factors also increased the risk of in-hospital complications for
24 women who underwent BCS. However, among those who underwent mastectomy, only
25 comorbidity was associated with a higher rate of in-hospital complications.

26

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2 DISCUSSION

3 T2DM is considered to be a common comorbidity that is present in many breast cancer patients,
4 correlating with poor clinical outcomes. [17,18] According to information obtained from the
5 SNHDD, compared with nondiabetic counterparts, women with T2DM undergoing surgical
6 breast cancer procedures have more risk factors, comorbidities and advanced cancer
7 presentations.

8 Several studies have reported that the presence of risk factors, such as hypertension and obesity,
9 are common in both patients with diabetes and those with breast cancer. [19,20]

10 In our current study, women with T2DM were significantly more likely to suffer from
11 advanced-stage breast cancer when compared with women without diabetes. Our findings are
12 consistent with other studies demonstrating a more advanced stage of breast cancer among
13 women with diabetes. [21, 22] A study conducted in Canada showed that diabetes was
14 associated with more advanced-stage breast cancer, even after accounting for differences in
15 screening mammogram use and other factors. [23] There are several possible explanations for
16 this association, including the fact that mammograms are less sensitive for the detection of early
17 lesions in women with T2DM because of higher rates of obesity. [24] Finally, tumors may
18 progress more rapidly in patients with diabetes, or diabetes may lead to a higher metastatic
19 potential. [25]

20 We observed that mastectomies are performed more frequently on diabetic women, which could
21 be explained by several factors, including higher comorbidity, higher stage disease at diagnosis,
22 the presence of more biologically aggressive tumors and the fact that diabetes is a major risk
23 factor in breast cancer recurrence. [3, 25] Kaplan et al. examined 483 breast cancer patients who
24 had undergone a mastectomy between 1998 and 2010. They concluded that the recurrence of
25 breast cancer was significantly increased in patients with diabetes (OR, 2.21; 95%CI 1.23–3.96;
26 $p=0.008$). [26]

27 As expected, we observed that in-hospital mortality and complication rates in breast cancer
28 surgery were low. This finding is consistent with de Blacam et al., who, in a multi-institutional

1 study of patients undergoing mastectomy and BCS in the US, found that the overall 30-day
2 morbidity rate was 5.6% for all procedures. [7]

3 We found that women with T2DM who underwent breast cancer surgical procedures had a
4 higher frequency of overall in-hospital complications compared with women without diabetes.
5 Several studies have reported that diabetes is a risk factor for surgical site infections after breast
6 operations. [7] A systematic review/meta-analysis concluded that patients with diabetes were
7 more vulnerable to surgical site infections after breast cancer surgery (OR 1.88, 95%CI 1.47–
8 2.39). [27]

9 In this study, comorbidity was a strong predictor of in-hospital complications in women with
10 T2DM who underwent surgical breast cancer-related procedures. Dehal et al. studied the impact
11 of comorbidity using hospital discharge data from the “Health Care Utilization Project:
12 Nationwide In-patient Sample” database in women with a primary diagnosis of breast cancer
13 after undergoing breast surgery. They found that women with a severe (CCI score ≥ 3)
14 comorbidity were 4.6-times more likely to develop a postoperative complication when
15 compared with patients without a comorbidity. [28]

16 In our present study, obesity was a predictor of IHC in women with diabetes who underwent
17 BCS. Being overweight or obese has been associated with higher rates of treatment-related
18 sequelae, such as lymphedema, fatigue and arthralgia. [29] Helyer et al. concluded that obesity
19 is a risk factor for the development of postoperative lymphedema in breast cancer patients (OR
20 1.8; 95%CI, 1.0004–1.165). [30] Excess adiposity may increase the risk of lymphedema by
21 driving increased inflammation, adding stress to the lymphatic system, or slowing post-surgical
22 healing times. [31] However, as will be commented in the limitations section the uncertainty
23 regarding the validity of the obesity codification in the SNHDD requires caution when
24 interpreting this result.

25 The strengths of our study included its large simple size, the standardized methodology, and use
26 of age- and province-matched non-T2DM patients to control for the confounding effects of
27 these variables. However, our study has several limitations. First, the validity of the T2DM must
28 be discussed. A study conducted to validate the diabetes mellitus diagnosis in the computerized

1
2
3 1 clinical records of primary health care in Spain, taking the 2003 ADA Consensus Statement as
4
5 2 the gold standard, found that the agreement was very high ($\kappa=0.990$), with a specificity of
6
7 3 99.49% and a sensitivity of 99.53%. [14] The validity of the diabetes diagnosis in the SNHDD
8
9 4 has been assessed in two previous studies, revealing a sensitivity of 55% and 63.7% and a
10
11 5 specificity of approximately 97%. [10,11]
12
13 6 The only moderate sensitivity found means that an important proportion of T2DM patients do
14
15 7 not have this diagnosis codified in their discharge report. On the other hand, the very high
16
17 8 specificity means that most patients without a T2DM diagnosis do not really have this disease;
18
19 9 therefore, we think that the effect of this misclassification on our design is possibly very small.
20
21 10 Furthermore, the database was designed for administrative rather than research purposes,
22
23 11 therefore conditions such as obesity, infection, hypertension and smoking may not have been
24
25 12 adequately recorded in the database. [8, 10, 11]
26
27 13 The validity of the variable “obesity” in our investigation must be discussed. In our study
28
29 14 population, the prevalence of obesity is very low among women with diabetes, which is
30
31 15 possibly a consequence of under-recording this condition. Previous studies conducted in Spain
32
33 16 and other countries have also found an under-reporting of obesity in administrative data. [32-35]
34
35 17 These authors suggest the following possible reasons to explain the low rates of obesity in
36
37 18 administrative data: i) obesity is not explicitly mentioned in physician reports; ii) people who
38
39 19 codify may not record obesity owing to time constraints when performing data abstraction; iii)
40
41 20 when time for coding is limited, coders tend to include severe conditions but not risk factors
42
43 21 and; iv) the diagnosis of obesity is often not based on the BMI, but rather on the subjective
44
45 22 observation made by the clinician, which means that more severe obesity is over-codified [33-
46
47 23 35] Furthermore, a possible differential information bias may occur and thus the
48
49 24 misclassification of obesity may be related to the presence of diabetes. Thus, ICD codes for
50
51 25 obesity may be more commonly assigned to patients suffering from other comorbidities
52
53 26 (including diabetes) or postoperative complications. This suggests a greater association between
54
55 27 obesity and adverse events than what is obtained based on the BMI calculations. [33, 35] As a
56
57
58
59
60

1 result, any association between obesity and the presence of in-hospital complications must be
2 interpreted with caution.

3 Second, unfortunately the ICD 9 does not include information regarding whether a condition is
4 part of the patient's past medical history or if this appeared during the hospitalization.
5 Therefore, it is possible that a patient may first be diagnosed with diabetes or any other
6 condition studied during the hospitalization. However, we think that this possibly affects a very
7 small proportion of patients and thus the effect on our results would be minimal.

8 Third, the database that we used contained no information about chemotherapy or radiotherapy
9 treatments prior to surgery, which may have affected our outcome variables.

10 Forth, we lacked data such as breast cancer characteristics or the time span since diagnosis.

11 Finally, other relevant variables such as laboratory results, BMI, medical treatments (e.g.
12 glucose lowering drugs, insulin or antibiotics), patients who have undergone a prosthetic
13 reconstruction and the eventual use of an acellular dermal matrix are not included in the
14 SNHDD.

16 CONCLUSIONS

17 We conclude that women with T2DM who undergo surgical procedures to treat breast cancer
18 have more comorbidities, risk factors and a more advanced cancer presentation than women
19 without T2DM. Mastectomies are more frequently performed in diabetic women. Moreover,
20 procedures carried out in women with T2DM were associated with greater in-hospital
21 complications. Finally, comorbidity was a strong predictor of in-hospital complications in
22 women with T2DM.

1
2
3 **1 ACKNOWLEDGEMENTS**

4
5 2 We would like to thank the Spanish Ministry of Health and Social Policy for providing the
6
7 3 records of the SNHDD (Conjunto Mínimo Básico de Datos).

8
9 **4 CONTRIBUTIONS**

10
11 5 Ana López-de-Andres and Rodrigo Jiménez-García participated in the conception and design,
12
13 6 analysis, interpretation, and writing of the manuscript. Valentín Hernández-Barrera and Isabel
14
15 7 Jiménez-Trujillo contributed their statistical expertise and towards conception and design,
16
17 8 interpretation and writing of the manuscript. Javier de Miguel-Díez, Manuel Méndez-Bailón,
18
19 9 José M de Miguel-Yanes, Napoleón Pérez-Farinós, Miguel-Angel Salinero-Fort, José L del
20
21 10 Barrio and Martín Romero-Maroto were involved in the critical revision of the manuscript, as
22
23 11 well as the interpretation and design. All authors have seen and approved the final version.

24
25 **12 COMPETING INTERESTS**

26
27 13 The authors declare that they have no competing interests.

28
29 **14 DATA SHARING STATEMENT**

30
31 15 "No additional data available"

32
33 **16 FUNDING**

34
35 17 This study is part of research funded by the FIS (Fondo de Investigaciones Sanitarias-Health
36
37 18 Research Fund, grants no. PI13/00118 and PI16/00564, Instituto de Salud Carlos III) co-
38
39 19 financed by the European Union through the Fondo Europeo de Desarrollo Regional (FEDER,
40
41 20 "Una manera de hacer Europa") and by the Grupo de Excelencia Investigadora URJC-Banco
42
43 21 Santander N°30VCPIGI03: Investigación traslacional en el proceso de salud - enfermedad
44
45 22 (ITPSE).
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 REFERENCES

- 2 1. Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer
3 incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-
4 years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease
5 study. *JAMA Oncol* 2017;3(4):524-548.
- 6 2. Raine R, Wong W, Scholes S, et al. Social variations in access to hospital care for patients
7 with colorectal, breast and lung cancer between 1999 and 2006: retrospective analysis of
8 hospital episode statistics. *BMJ* 2010;340:b5479.
- 9 3. Escribà JM, Pareja L, Esteban L, et al. Trends in the surgical procedures of women with
10 incident breast cancer in Catalonia, Spain, over a 7-year period (2005–2011). *BMC Res Notes*
11 2014; 7:587.
- 12 4. Chang JM, Kosiorek HE, Dueck AC, et al. Trends in mastectomy and reconstruction for
13 breast cancer; a twelve year experience from a tertiary care center. *Am J Surg*
14 2016;212(6):1201-10.
- 15 5. Pyfer B, Chatterjee A, Chen L, et al. Early postoperative outcomes in breast conservation
16 surgery versus simple mastectomy with implant reconstruction: a NSQIP analysis of 11,645
17 patients. *Ann Surg Oncol* 2016;23(1):92-8.
- 18 6. El-Tamer MB, Ward BM, Schiffner T, et al. Morbidity and mortality following breast cancer
19 surgery in women: national benchmarks for standards of care. *Ann Surg* 2007;245(5):665-71.
- 20 7. de Blacam C, Ogunleye AA, Momoh AO, et al. High body mass index and smoking predict
21 morbidity in breast cancer surgery: a multivariate analysis of 26,988 patients from the national
22 surgical quality improvement program database. *Ann Surg* 2012;255(3):551-5.
- 23 8. Ministerio de Sanidad, Servicios Sociales e Igualdad. Registro de Altas de los Hospitales
24 Generales del Sistema Nacional de Salud. CMBD. Available from
25 <https://www.msssi.gob.es/estadEstudios/estadisticas/cmbdhome.htm>. Accessed 30 August 2017.
- 26 9. Estudio de las comorbilidades que componen el índice de Elixhauser. Análisis de prevalencia
27 y fiabilidad en los registros del CMBD estatal de hospitalización Available from
28 <http://icmbd.es/docs/informe-comorbilidades-1.pdf> Accessed 30 August 2017.

10. Ribera A, Marsal JR, Ferreira-González I, Cascant P, et al. Predicting in-hospital mortality with coronary bypass surgery using hospital discharge data: comparison with a prospective observational study. *Rev Esp Cardiol* 2008; 61(8):843-852.
11. Rodrigo-Rincón I, Martín-Vizcaíno MP, Tirapu-León B, et al. Usefulness of administrative databases for risk adjustment of adverse events in surgical patients. *Cir Esp*. 2016;94(3):165-74.
12. Calle JE, Saturno PJ, Parra P, et al. Quality of the information contained in the minimum basic data set: Results from an evaluation in eight hospitals. *Eur J Epidemiol*. 2000; 16: 1073-80
13. Hernández Medrano I, Guillán M, Masjuan J, et al. Reliability of the minimum basic dataset for diagnoses of cerebrovascular disease. *Neurologia*. 2017;32(2):74-80.
14. de Burgos-Lunar C, Salinero-Fort MA, Cárdenas-Valladolid J, et al. Validation of diabetes mellitus and hypertension diagnosis in computerized medical records in primary health care. *BMC Med Res Methodol*. 2011;11:146.
15. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373-83.
16. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care* 2005;43:1130-9.
17. Lipscombe LL, Goodwin PJ, Zinman B, et al. The impact of diabetes on survival following breast cancer. *Breast Cancer Res Treat* 2008;109(2):389-95.
18. Peairs KS, Barone BB, Snyder CF, et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. *J Clin Oncol* 2011; 29(1):40-6.
19. Patterson RE, Flatt SW, Saquib N, et al. Medical comorbidities predict mortality in women with a history of early stage breast cancer. *Breast Cancer Res Treat* 2010;122(3):859-65.
20. Jousheghany F, Phelps J, Crook T, et al. Relationship between level of HbA1C and breast cancer. *BBA Clin* 2016;6:45-8.
21. Srokowski TP, Fang S, Hortobagyi GN, et al. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. *J Clin Oncol* 2009;27(13):2170-2176.

- 1
2
3 1 22. van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, et al. Less aggressive treatment
4 and worse overall survival in cancer patients with diabetes: a large population based analysis.
5
6 2
7 3 *Int J Cancer* 2007; 120(9):1986–1992.
8
9 4 23. Lipscombe LL, Fischer HD, Austin PC, et al. The association between diabetes and breast
10 cancer stage at diagnosis: a population-based study. *Breast Cancer Res Treat* 2015;150(3):613-
11 620.
12
13 7 24. Kerlikowske K, Walker R, Miglioretti DL, et al. Obesity, mammography use and accuracy,
14 and advanced breast cancer risk. *J Natl Cancer Inst* 2008;100(23):1724–1733.
15
16 9 25. Godsland IF. Insulin resistance and hyperinsulinaemia in the development and progression
17 of cancer. *Clin Sci* 2010;118(5):315–332.
18
19 10 26. Kaplan MA, Pekkola Z, Kucukoner M, et al. Type 2 diabetes mellitus and prognosis in
20 early stage breast cancer women. *Med Oncol* 2012;29(3):1576-1580.
21
22 11 27. Xue DQ, Qian C, Yang L, et al. Risk factors for surgical site infections after breast surgery:
23 a systematic review and meta-analysis. *Eur J Surg Oncol* 2012;38(5):375-381.
24
25 12 28. Dehal A, Abbas A, Johna S. Comorbidity and outcomes after surgery among women with
26 breast cancer: analysis of nationwide in-patient sample database. *Breast Cancer Res Treat*
27 2013;139(2):469-476.
28
29 13 29. Ridner S, Dietrich M, Stewart R, et al. Body mass index and breast cancer treatment-related
30 lymphedema. *Support Care Cancer* 2011;19:853–857.
31
32 14 30. Helyer LK, Varnic M, Le LW, et al. Obesity is a risk factor for developing postoperative
33 lymphedema in breast cancer patients. *Breast J* 2010;16(1):48-54.
34
35 15 31. Ahmed RL, Schmitz KH, Prizment AE, Folsom AR. Risk factors for lymphedema in breast
36 cancer survivors, the Iowa Women’s Health Study. *Breast Cancer Res Treat* 2011;130(3):981–
37 991.
38
39 16 32. Sánchez-Muñoz LA. Nutritional status, heart failure and minimum basic data set. *Rev Esp*
40 *Cardiol (Engl Ed)*. 2012 Jun;65(6):583.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 33. Martin BJ, Chen G, Graham M, et al. Coding of obesity in administrative hospital discharge
4
5 2 abstract data: accuracy and impact for future research studies. BMC Health Serv Res. 2014 Feb
6
7 3 13;14:70.
8
9 4 34. Lujic S, Watson DE, Randall DA, et al. Variation in the recording of common health
10
11 5 conditions in routine hospital data: study using linked survey and administrative data in New
12
13 6 South Wales, Australia. BMJ Open. 2014 Sep 3;4(9):e005768.
14
15 7 35. McLynn RP, Geddes BJ, Cui JJ, et al. Inaccuracies in ICD Coding for Obesity Would be
16
17 8 Expected to Bias Administrative Database Spine Studies Toward Overestimating the Impact of
18
19 9 Obesity on Perioperative Adverse Outcomes. Spine (Phila Pa 1976). 2017 Aug 1. doi:
20
21 10 10.1097/BRS.0000000000002356.
22
23 11
24
25 12 .
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Clinical characteristics, complications and hospital outcomes of hospital admissions for breast cancer and according to type of surgical procedure among women suffering type 2 diabetes and matched women without type 2 diabetes.

	Total (n=6,836)			Breast conservative surgery (n=,3876)			Mastectomy (n=2,960)		
	Diabetes (n=3,418)	No diabetes (n=3,418)	p-value	Diabetes (n=1,938)	No diabetes (n=1,938)	p-value	Diabetes (n=1,480)	No diabetes (n=1,480)	p-value
Age, mean (SD)	70.14(10.22)	70.14(10.22)	NA	68.18(9.53)	68.18(9.53)	NA	72.71(10.51)	72.71(10.51)	NA
40-59 years old, n (%)	522(15.27)	522(15.27)	NA	343(17.7)	343(17.7)	NA	179(12.09)	179(12.09)	NA
60-79 years old, n (%)	2187(63.98)	2187(63.98)		1335(68.89)	1335(68.89)		852(57.57)	852(57.57)	
≥ 80 years old, n (%)	709(20.74)	709(20.74)		260(13.42)	260(13.42)		449(30.34)	449(30.34)	
Stage: Local, n (%)	2590(75.78)	2590(75.78)	NA	1560(80.5)	1560(80.5)	NA	1030(69.59)	1030(69.59)	NA
Stage: Regional, n (%)	799(23.38)	799(23.38)		371(19.14)	371(19.14)		428(28.92)	428(28.92)	
Stage: Distant, n (%)	29(0.85)	29(0.85)		7(0.36)	7(0.36)		22(1.49)	22(1.49)	
CCIO, n (%)	2798(81.86)	3050(89.23)	<0.001	1627(83.95)	1763(90.97)	<0.001	1171(79.12)	1287(86.96)	<0.001
CCI1, n (%)	522(15.27)	324(9.48)		274(14.14)	155(8)		248(16.76)	169(11.42)	
CCI≥2, n (%)	98(2.87)	44(1.29)		37(1.91)	20(1.03)		61(4.12)	24(1.62)	
Vascular disease, n (%)	301(8.81)	226(6.61)	<0.001	159(8.2)	119(6.14)	0.011	142(9.59)	107(7.23)	0.019
Renal disease, n (%)	141(4.13)	48(1.40)	<0.001	61(3.15)	24(1.24)	<0.001	80(5.41)	24(1.62)	<0.001
Stroke/TIA/TEP, n (%)	82(2.40)	55(1.61)	0.020	31(1.60)	22(1.14)	0.201	51(3.45)	33(2.23)	0.051
Congestive heart failure, n (%)	66(1.93)	21(0.61)	<0.001	21(1.08)	9(0.46)	0.020	45(3.04)	12(0.81)	<0.001
Acute myocardial infarction, n (%)	33(0.97)	18(0.53)	0.039	21(1.08)	7(0.36)	0.012	12(0.81)	11(0.74)	0.835
Obesity, n (%)	450(13.17)	124(3.63)	<0.001	267(13.78)	70(3.61)	<0.001	183(12.36)	54(3.65)	<0.001
Hypertension, n (%)	2240(65.54)	1238(36.22)	<0.001	1267(65.38)	654(33.75)	<0.001	973(65.74)	584(39.46)	<0.001
Smoking, n (%)	166(4.86)	185(5.41)	0.288	111(5.73)	121(6.24)	0.488	55(3.72)	64(4.32)	0.393
Sentinel lymph node dissection, n (%)	1697(49.65)	1795(52.52)	0.092	1184(61.09)	1257(64.86)	0.032	513(34.66)	538(36.35)	0.332
Axillary lymph node dissection, n (%)	560(16.38)	551(16.12)	0.747	375(19.35)	382(19.71)	0.752	185(12.5)	169(11.42)	0.349
Infectious complications, n (%)	95(2.78)	76(2.22)	0.138	35(1.81)	22(1.14)	0.088	60(4.05)	54(3.65)	0.560
Non infectious complications, n(%)	219(6.40)	156(4.56)	0.004	93(4.80)	53(2.73)	0.015	126(8.51)	103(6.96)	0.032
All complications (infectious and/or non infectious), n (%)	264(7.72)	181(5.30)	0.003	107(5.57)	59(3.04)	0.008	157(10.60)	122(8.24)	0.029
Length of stay, median (IQR)	3(2-5)	3(2-5)	0.070	2(1-3)	2(1-3)	0.065	4(3-6)	4(3-6)	0.062
In-hospital mortality, n (%)	5(0.15)	2(0.06)	0.277	2(0.1)	1(0.05)	0.571	3(0.2)	1(0.07)	0.341

CCI: Charlson Comorbidity Index. IQR: Interquartile range. P value for difference between T2DM sufferers and matched controls using bivariate conditional logistic regression. Matching was conducted by age, province of residence, type of surgical procedure and stage.

1 **Table 2.** Logistic regression analysis of the factor associated with in-hospital complications in women with type 2 diabetes during
2 hospital admission for breast cancer according to the type of surgical procedure.

		Any breast cancer surgical procedure (Conservative or mastectomy) OR (95%CI)	Breast Conservative Surgery OR (95%CI)	Mastectomy OR (95%CI)
Age groups, years	40-59	1	1	1
	60-79	0.98 (0.70-1.37)	0.79 (0.50-1.26)	1.12 (0.67-1.86)
	≥ 80	1.16 (0.79-1.71)	0.92 (0.50-1.67)	1.22 (0.71-2.10)
CCI	0	1	1	1
	1	1.72(1.30-2.27)	1.75(1.12-2.71)	1.64(1.14-2.35)
	≥2	2.55(1.55-4.17)	3.33(1.48-7.48)	2.10(1.13-3.91)
Stage	Local	1	1	1
	Regional/distant	1.21 (0.98-1.48)	1.08(0.74-1.55)	1.19(0.93-1.52)
Obesity	Yes	1.54 (1.14-2.07)	1.68 (1.07-2.60)	1.46(0.98-2.19)

3 CCI: Charlson Comorbidity Index. OR: Odds Ratio. 95%CI: 95% confidence intervals. All variables included in the models are shown.

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-4
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5,6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5,6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6,7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-8
Bias	9	Describe any efforts to address potential sources of bias	6-8
Study size	10	Explain how the study size was arrived at	6-8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8,9
		(b) Describe any methods used to examine subgroups and interactions	8,9
		(c) Explain how missing data were addressed	
		(d) If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	9-17
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest	9-17
Outcome data	15*	Report numbers of outcome events or summary measures	9-17
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9-17
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	18-20
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	18-20
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	18-20
Generalisability	21	Discuss the generalisability (external validity) of the study results	20,21
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	22

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.